[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2662
1. Shaw BE, Russell NH: Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. Bone Marrow Transplant; 2008 Mar;41(5):495-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.
  • The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952130.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors
  • [Number-of-references] 91
  •  go-up   go-down


2. Essa EA, El Halim SM, Abo-Elenin A, El Bendary A, Abdou SH, Farag W: Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia. Egypt J Immunol; 2007;14(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of gene expression of CD30 variant (CD30v) and CD30 ligand (CD30L) in acute leukemia.
  • In this work, reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the gene expression (mRNA) of CD30 variant (CD30v) and CD30 Ligand (CD30L) on the peripheral blood mononuclear cells (PBMCs) of 15 healthy individuals as a control group, 15 patients with newly diagnosed acute myeloid leukemia (AML) and 15 patients with newly diagnosed acute lymphocytic leukemia (ALL).
  • Patients with positive expression of CD30v and CD30L were found to have significantly increased blast cell % (p<0.001), increased total leucocytic count (P<0.001) and decreased platelets count (P<0.001) than those with negative expression.
  • As regard to immunophenotypes of ALL, positive expression was found to be significantly higher in B-cell than T-cell subtype (77.8% versus 16.7%, P=0.02).
  • Positive expression was also significantly associated with more aggressive disease and with B-cell than T-cell subtypes.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689277.001).
  • [ISSN] 1110-4902
  • [Journal-full-title] The Egyptian journal of immunology
  • [ISO-abbreviation] Egypt J Immunol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / CD30 Ligand; 0 / RNA, Messenger
  •  go-up   go-down


3. Braham-Jmili N, Sendi-Senana H, Labiadh S, Ben Abdelali R, Ben Abdelaziz A, Khelif A, Saad A, Kortas M: [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia]. Ann Biol Clin (Paris); 2006 Sep-Oct;64(5):457-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Haematological characteristics, FAB and WHO classification of 153 cases of myeloid acute leukaemia in Tunisia].
  • [Transliterated title] Caractéristiques hématologiques et classification FAB et OMS de 153 cas de leucémies aiguës myéloïdes en Tunisie.
  • A complete blood analysis with a careful morphologic examination of peripheral blood and bone morrow smears completed by cytochemical reaction will help to classify the most acute myeloid leukaemia (AML).
  • Actually, the study of other cytogenetis and immunophenotypic markers are now necessary to confirm diagnosis.
  • The morphologic conclusion was difficult in 12% cases.
  • In WHO classification, cytology is essential in diagnosis of LAM even if the karytype have an important prognostic value.
  • [MeSH-major] Leukemia, Myeloid / classification
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Chromosome Aberrations. Diagnosis, Differential. Female. Humans. Infant. Karyotyping. Leukemia, Erythroblastic, Acute / blood. Leukemia, Erythroblastic, Acute / diagnosis. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Myelomonocytic, Acute / blood. Leukemia, Myelomonocytic, Acute / diagnosis. Leukemia, Myelomonocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / diagnosis. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged. Retrospective Studies. Tunisia. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040877.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Kassim AA, Chinratanalab W, Ferrara JL, Mineishi S: Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'. Bone Marrow Transplant; 2005 Oct;36(7):565-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.
  • Reduced-intensity stem cell transplantation (RIST) has been shown to be a safe and useful alternative transplant method for patients including elderly and medically unfit patients.
  • RIST conditioning regimens vary widely in the intensity of myeloablation, immunoablation, and antileukemia effects, and thus optimal regimen for each disease entity is yet to be determined.
  • In acute myeloid leukemia (AML), moderate-intensity regimens may be effective, achieving 30-70% 1-year disease-free survival in various series, but minimal-intensity regimens are associated with high relapse rates.
  • In acute lymphoblastic leukemia (ALL), not even moderate-intensity regimens are effective and most patients with advanced ALL relapse post transplant.
  • Thus, the risk/benefit ratios of graft-versus-host disease/graft-versus-leukemia effect differ among diseases.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Clinical Trials as Topic. Disease-Free Survival. Graft vs Host Disease. Humans. Middle Aged. Multicenter Studies as Topic. Recurrence. Time Factors. Transplantation Chimera. Transplantation Conditioning. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15995714.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


5. Kiefel V, Greinacher A: [Differential diagnosis and treatment of thrombocytopenia]. Internist (Berl); 2010 Nov;51(11):1397-410
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis and treatment of thrombocytopenia].
  • Important differential diagnoses in patients with severe thrombocytopenia are: acute leukemia, thrombotic thrombocytopenic purpura, autoimmune thrombocytopenia and drug-dependent thrombocytopenia.
  • Treatment should focus on the underlying disease.
  • [MeSH-major] Thrombocytopenia / diagnosis. Thrombocytopenia / etiology
  • [MeSH-minor] Chromosomes, Human, Pair 22 / genetics. DNA Mutational Analysis. Diagnosis, Differential. Female. Humans. Molecular Motor Proteins / genetics. Myosin Heavy Chains / genetics. Platelet Count. Pregnancy. Reference Values

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Onkologie. 2010;33 Suppl 3:2-20 [20484949.001]
  • [Cites] Hamostaseologie. 2006 Jan;26(1):72-4; quiz 75-8 [16444327.001]
  • [Cites] Ann Intern Med. 2001 Oct 16;135(8 Pt 1):589-93 [11601930.001]
  • [Cites] Haematologica. 2007 Sep;92(9):1158-64 [17768118.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Apr;28(4):619-24 [15100613.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):169-81 [3317856.001]
  • [Cites] Curr Opin Hematol. 2008 Sep;15(5):445-50 [18695366.001]
  • [Cites] Haematologica. 2003 May;88(5):582-92 [12745278.001]
  • [Cites] Semin Thromb Hemost. 2009 Mar;35(2):189-203 [19408192.001]
  • [Cites] Int J Hematol. 2005 Feb;81(2):119-25 [15765779.001]
  • [Cites] Hamostaseologie. 2010 Jan;30(1):17-8, 20-8 [20162249.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2009;:153-8 [20008194.001]
  • [Cites] N Engl J Med. 1994 Jun 2;330(22):1560-4 [8177245.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6288-95 [19351959.001]
  • (PMID = 20941473.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / MYH9 protein, human; 0 / Molecular Motor Proteins; EC 3.6.4.1 / Myosin Heavy Chains
  •  go-up   go-down


6. Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS: Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr; 2006 May;148(5):687-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder.
  • Transient myeloproliferative disorder (TMD) occurs in 10% of infants with Down syndrome (DS).
  • Down syndrome infants with resolved TMD may later develop acute megakaryocytic leukemia (AMKL).
  • We report on a non-DS child identified with trisomy 21 mosaicism and a GATA1 mutation in the original blast cells who has been followed for 2 years without exhibiting AMKL.
  • Currently, the risk for such infants developing acute leukemia is uncertain.
  • [MeSH-major] GATA1 Transcription Factor / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Myeloproliferative Disorders / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr. 2007 Mar;150(3):e34 [17307526.001]
  • (PMID = 16737888.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor
  •  go-up   go-down


7. Chabrol A, Cuzin L, Huguet F, Alvarez M, Verdeil X, Linas MD, Cassaing S, Giron J, Tetu L, Attal M, Récher C: Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia. Haematologica; 2010 Jun;95(6):996-1003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia.
  • BACKGROUND: Invasive aspergillosis is a common life-threatening infection in patients with acute leukemia.
  • This study assessed the impact of voriconazole or caspofungin prophylaxis in patients undergoing induction chemotherapy for acute leukemia in a hematology unit exposed to building work.
  • The diagnosis of invasive aspergillosis was based on the European Organization for Research and Treatment of Cancer/Mycosis Study Group criteria.
  • RESULTS: Two-hundred and fifty-seven patients (213 with acute myeloid leukemia, 44 with acute lymphocytic leukemia) were included.
  • Invasive aspergillosis was diagnosed in 21 patients (12%) in the non-prophylaxis group and four (4.5%) in the prophylaxis group (P=0.04).
  • Pulmonary antecedents, neutropenia at diagnosis and acute myeloid leukemia with high-risk cytogenetics were positively correlated with invasive aspergillosis, whereas primary prophylaxis was negatively correlated.
  • CONCLUSIONS: This study suggests that antifungal prophylaxis with voriconazole could be useful in acute leukemia patients undergoing first remission-induction chemotherapy in settings in which there is a high-risk of invasive aspergillosis.
  • [MeSH-major] Air Pollutants / adverse effects. Construction Materials / adverse effects. Echinocandins / administration & dosage. Invasive Pulmonary Aspergillosis / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / administration & dosage. Triazoles / administration & dosage

  • Genetic Alliance. consumer health - Aspergillosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):911-8 [19124805.001]
  • [Cites] Am J Hematol. 2001 Apr;66(4):257-62 [11279636.001]
  • [Cites] J Hosp Infect. 2001 Jul;48(3):198-206 [11439007.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:54-61 [11525219.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):288-96 [12183144.001]
  • [Cites] Infect Control Hosp Epidemiol. 1990 May;11(5):235-42 [2351809.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1752-7 [10325319.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1928-35 [16284057.001]
  • [Cites] Leukemia. 2006 Mar;20(3):400-3 [16437142.001]
  • [Cites] J Hosp Infect. 2006 Jul;63(3):246-54 [16713019.001]
  • [Cites] Diagn Microbiol Infect Dis. 2006 Jul;55(3):209-12 [16626917.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):738-44 [16842568.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1068-75 [16885047.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):348-59 [17251531.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1289-97 [17443465.001]
  • [Cites] Blood. 2007 Aug 1;110(3):1025-8 [17426258.001]
  • [Cites] J Infect. 2007 Nov;55(5):445-9 [17822770.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1327-34 [18024370.001]
  • [Cites] Clin Infect Dis. 2008 Jun 15;46(12):1813-21 [18462102.001]
  • [Cites] Clin Infect Dis. 2001 Feb 1;32(3):358-66 [11170942.001]
  • (PMID = 20007135.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC2878800
  •  go-up   go-down


8. El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF: Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Canc Inst; 2006 Sep;18(3):244-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia.
  • BACKGROUND: Immunophenotyping improves both accuracy and reproducibility of acute leukemia classification and is considered particularly useful for identifying aberrant lineage association of acute leukemia, biphenotypic and bilineal acute leukemia, as well as monitoring minimal residual disease.
  • THE AIM OF OUR STUDY: Is to determine aberrant lymphoid antigen expression in Saudi acute myeloid leukemia (AML), correlate them with FAB subtypes, evaluate early surface markers CD7 and CD56, and to investigate the role of cytoplasmic CD79a (a B cell marker that is assigned a high score of 2.0 in the WHO classification).
  • CD79a was expressed in one case together with CD19, diagnosed as acute biphenotypic leukemia, and was associated with t(8;21) (q22;q22).
  • CONCLUSION: Minimal residual disease in AML is very difficult to trace, detection of aberrant expression of lymphoid antigens will make it easier.
  • [MeSH-major] Antigens, CD56 / analysis. Antigens, CD7 / analysis. Antigens, CD79 / analysis. Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Leukemia, Myeloid, Acute / diagnosis


9. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


10. Torres T JP, Concha V E, López G JP, Cofre G J: [Acute retinal necrosis in an acute leukemia pediatric patient]. Rev Chilena Infectol; 2007 Aug;24(4):323-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute retinal necrosis in an acute leukemia pediatric patient].
  • [Transliterated title] Necrosis retinal aguda en un paciente pediátrico con leucemia aguda.
  • Acute retinal necrosis (ARN) is a serious condition that can impair vision.
  • It mostly occurs in adult patients, especially those severely immunocompromised, in association with a reactivation of a herpes virus infection.
  • We present a 4 years old patient with high risk acute leukemia, whom during a course of intense chemotherapy acquired chickenpox with visceral involvement that affected the retina, causing unilateral blindness.
  • [MeSH-major] Chickenpox / complications. Immunocompromised Host. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Retinal Necrosis Syndrome, Acute / virology

  • MedlinePlus Health Information. consumer health - Chickenpox.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728923.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


11. Chandrasekar P: Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation. Med Mycol; 2009;47 Suppl 1:S349-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
  • Availability of newer, well tolerated anti-Aspergillus drugs at a time of rising prevalence of invasive aspergillosis has sparked enthusiasm for chemoprophylaxis against Aspergillus in allogeneic stem cell recipients.
  • Posaconazole, approved for prophylaxis in allogeneic stem cell recipients with graft versus host disease and in those with acute leukemia, is of promise but has a limitation relating to its oral bioavailability.
  • [MeSH-major] Aspergillosis / prevention & control. Chemoprevention / methods. Stem Cell Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663660.001).
  • [ISSN] 1460-2709
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 33
  •  go-up   go-down


12. Guan LJ, Zhang JH, Wang YX, Zhang N, Hu YP, Li ZG, Zhao W: [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1119-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ubiquitin associated protein 1 gene and tumor-suppressor gene p16 in acute leukemia].
  • In order to investigate the expression and the relationship of ubiquitin associated protein 1 (ubap1) gene and tumor-suppressor gene p16 in acute leukemia, 68 cases of acute leukemia and 22 control cases were selected in this experiment, FQ-PCR technique was used to detect the mRNA expression level of ubap1 gene and p16 gene in their bone marrow cells.
  • The results showed that as compared with the control group, the ubap1 gene in acute leukemia group highly expressed (p<0.01), while the p16 gene lowly expressed (p<0.01).
  • In addition to this, the ubap1 gene and p16 gene mRNA expression in AL was not relate with chromosome abnormality (p>0.05).
  • It is concluded that the upregulation of ubap1 gene expression mainly and the downregulation of p16 gene expression mainly may simultaneously participate in the pathogenesis of acute leukemia.

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129243.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / UBAP1 protein, human
  •  go-up   go-down


13. Rivera-Del Valle N, Gao S, Miller CP, Fulbright J, Gonzales C, Sirisawad M, Steggerda S, Wheler J, Balasubramanian S, Chandra J: PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells. Int J Cell Biol; 2010;2010:207420
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
  • In the present study, we show that apoptosis induction and histone alterations by PCI-24781, a novel hydroxamic acid-based HDAC inhibitor, require caspase-8 and the adaptor molecule, Fas-associated death domain (FADD), in acute leukemia cells.
  • Taken together, these results provide insight into the mechanism of apoptosis induction by PCI-24781 in leukemia by highlighting the roles of caspase-8, FADD and increased superoxide levels.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):12001-8 [11812781.001]
  • [Cites] FEBS J. 2009 Aug;276(15):4256-65 [19583773.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9231-42 [14647441.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1207-14 [15116122.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Cell Death Differ. 2005 Jan;12(1):10-8 [15540114.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1309-17 [16731764.001]
  • [Cites] Exp Mol Med. 2006 Dec 31;38(6):616-24 [17202837.001]
  • [Cites] Blood. 2007 Jul 1;110(1):267-77 [17356134.001]
  • [Cites] Nature. 2007 May 24;447(7143):433-40 [17522677.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20 [17594194.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5541-52 [17694093.001]
  • [Cites] Autophagy. 2007 Nov-Dec;3(6):643-5 [17912024.001]
  • [Cites] Mol Med. 2008 Jan-Feb;14(1-2):20-7 [17973028.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):740-8 [18413789.001]
  • [Cites] J Biol Chem. 2008 Jul 11;283(28):19499-510 [18458084.001]
  • [Cites] Antioxid Redox Signal. 2009 May;11(5):1123-37 [19018667.001]
  • [Cites] Blood. 2009 Jul 9;114(2):380-93 [19383971.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3354-65 [19417023.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4512-9 [12920036.001]
  • (PMID = 20145726.001).
  • [ISSN] 1687-8884
  • [Journal-full-title] International journal of cell biology
  • [ISO-abbreviation] Int J Cell Biol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA115811
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2817379
  •  go-up   go-down


14. Georgy M, Yonescu R, Griffin CA, Batista DA: Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults. Cancer Genet Cytogenet; 2008 Aug;185(1):28-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute mixed lineage leukemia and a t(6;14)(q25;q32) in two adults.
  • Acute mixed lineage leukemia (AMLL) is a rare form of leukemia in which both myeloid and lymphoid markers are present.
  • Few chromosome abnormalities have been identified associated with this form of leukemia.
  • A translocation involving the long arms of chromosomes 6 and 14 was previously described in four young individuals with acute leukemia and in three of these cases the diagnosis was mixed lineage.
  • The rarity of the t(6;14) and the AMLL suggests a non-random association between these two events.
  • [MeSH-major] Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 6. Leukemia, Biphenotypic, Acute / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18656690.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Styczynski J, Gil L, Derwich K, Wachowiak J, Balwierz W, Badowska W, Krawczuk-Rybak M, Matysiak M, Wieczorek M, Balcerska A, Sonta-Jakimczyk D, Stefaniak J, Kowalczyk J, Urasinski T, Sobol G, Komarnicki M, Wysocki M: Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res; 2009 May;29(5):1643-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
  • The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • PATIENTS AND METHODS: The ex vivo drug resistance profile was analyzed in 282 patients, including 201 children with ALL de novo, 24 children with relapsed ALL, 25 children with AML de novo and 32 adults with AML.
  • RESULTS: Clofarabine had comparable ex vivo activity against lymphoblasts and myeloblasts, both on initial diagnosis and at relapse, both in children and in adults.
  • Its activity in acute myeloid leukemia was independent of patient age.
  • CONCLUSION: In comparison to childhood acute lymphoblastic leukemia, lack of differences in ex vivo activity gives rationale for use of clofarabine in refractory and relapsed pediatric and adult patients with acute myeloid leukemia.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443380.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


16. Andersson A, Ritz C, Lindgren D, Edén P, Lassen C, Heldrup J, Olofsson T, Råde J, Fontes M, Porwit-Macdonald A, Behrendtz M, Höglund M, Johansson B, Fioretos T: Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia; 2007 Jun;21(6):1198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status.
  • Gene expression analyses were performed on 121 consecutive childhood leukemias (87 B-lineage acute lymphoblastic leukemias (ALLs), 11 T-cell ALLs and 23 acute myeloid leukemias (AMLs)), investigated during an 8-year period at a single center.
  • Minimal residual disease status (MRD) in T-cell ALLs with a high (>0.1%) MRD at day 29 could be classified with 100% accuracy already at the time of diagnosis.
  • In pediatric leukemias with uncharacteristic cytogenetic aberrations or with a normal karyotype, unsupervised analysis identified two novel subgroups: one consisting mainly of cases remaining in complete remission (CR) and one containing a few patients in CR and all but one of the patients who relapsed.
  • This study of a consecutive series of childhood leukemias confirms and extends further previous reports demonstrating that global gene expression profiling provides a valuable tool for genetic and clinical classification of childhood leukemias.
  • [MeSH-major] Leukemia / classification. Leukemia / genetics. Neoplasm, Residual / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Acute Disease. Algorithms. Child. Gene Expression Profiling. Genes, cdc. Humans. Leukemia, B-Cell. Leukemia, Myeloid. Leukemia, T-Cell. Predictive Value of Tests. Recurrence. Remission Induction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410184.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


17. Loh AH, Chui CH: Port-A-Cath insertions in acute leukaemia and childhood malignancies. Asian J Surg; 2007 Jul;30(3):193-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Port-A-Cath insertions in acute leukaemia and childhood malignancies.
  • Incidence of catheter-related bloodstream infections (CRBSIs), other complications and CRBSI-related port removals were analysed for cases with acute leukaemia versus other malignancies.
  • While mean preoperative platelet count was 125.34 x 10(9)/L in children with acute leukaemia and 392.11 x 10(9)/L in those with other malignancies (p < 0.01), the incidence of all complications were similar between both subgroups.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638639.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Franklin JG, Paus MD, Pluetschow A, Specht L: Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk. Cochrane Database Syst Rev; 2005;(4):CD003187
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy, radiotherapy and combined modality for Hodgkin's disease, with emphasis on second cancer risk.
  • BACKGROUND: Second malignancies (SM) are a major late effect of treatment for Hodgkin's disease (HD).
  • OBJECTIVES: Radiotherapy (RT), chemotherapy (CT) and combined chemo-radiotherapy (CRT) for newly-diagnosed Hodgkin's disease are compared with respect to SM risk, overall (OS) and progression-free (PFS) survival.
  • Secondary acute leukemia (AL), non-Hodgkin's lymphoma (NHL) and solid tumours (ST) were also analysed separately.
  • [MeSH-major] Hodgkin Disease / drug therapy. Hodgkin Disease / radiotherapy. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16235316.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 127
  •  go-up   go-down


19. Mlombie Y: Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward. Malawi Med J; 2010 Jun;22(2):59-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward.
  • [MeSH-major] Burkitt Lymphoma. Leukemia
  • [MeSH-minor] Acute Disease. Humans. Malawi. Practice Patterns, Physicians' / trends

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1975 Feb;19(2):201-8 [1240046.001]
  • [Cites] S Afr Med J. 2009 Apr;99(4):243-8 [19588777.001]
  • [CommentOn] Malawi Med J. 2009 Jun;21(2):86, 88-9 [20345012.001]
  • (PMID = 21618748.001).
  • [ISSN] 1995-7262
  • [Journal-full-title] Malawi medical journal : the journal of Medical Association of Malawi
  • [ISO-abbreviation] Malawi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Malawi
  • [Other-IDs] NLM/ PMC3345756
  •  go-up   go-down


20. Thomas X, Campos L, Le QH, Guyotat D: Heat shock proteins and acute leukemias. Hematology; 2005 Jun;10(3):225-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock proteins and acute leukemias.
  • HSPs have also been implicated in the resistance of leukemia cells to potential therapeutic agents.
  • HSPs were shown highly expressed by acute myeloid leukemia (AML) cells as well as by acute lymphoblastic leukemia (ALL) cells.
  • [MeSH-major] Antineoplastic Agents / metabolism. Gene Expression Regulation, Leukemic / drug effects. HSP90 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Rifabutin / analogs & derivatives

  • Hazardous Substances Data Bank. RIFABUTIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019471.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Neoplasm Proteins; 1W306TDA6S / Rifabutin; 4GY0AVT3L4 / tanespimycin
  • [Number-of-references] 122
  •  go-up   go-down


21. Ennis MK, Dingli D: Death by fusion for acute leukemia cells. Cancer Biol Ther; 2010 Mar 1;9(5):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death by fusion for acute leukemia cells.
  • [MeSH-major] Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Biol Ther. 2010 Mar 1;9(5):350-7 [20061812.001]
  • (PMID = 20104027.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


22. Li R, Cao XH, Liu C, Wu XL, Ling YW, Zhang Y, Feng R, Liu QF: [Clinical implications of HLA-G protein expression in acute leukemia]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2446-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical implications of HLA-G protein expression in acute leukemia].
  • OBJECTIVE: To detect the expression of membrane-bound HLA-G (mHLA-G) and serum HLA-G (sHLA-G) in acute leukemia patients and investigate the correlation between HLA-G expression and the occurrence and development of acute leukemia.
  • METHODS: Enzyme-linked immunosorbent assay and flow cytometry were used to detect the expression levels of sHLA-G and mHLA-G in 40 newly diagnosed leukemia cases, 10 refractory and relapsed leukemia cases, and 30 leukemia cases receiving chemotherapy.
  • RESULTS: The mean serum level of sHLA-G in normal individuals was 5.87±2.07 ng/ml, as compared to 10.05±6.58 ng/ml in newly diagnosed leukemia patients and 12.32±5.85 ng/ml in refractory and relapsed cases.
  • CONCLUSION: HLA-G expression levels might influence the treatment outcomes and can serve as a prognostic factor for acute leukemia.
  • [MeSH-major] HLA-G Antigens / metabolism. Leukemia / metabolism. Leukemia / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097401.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / HLA-G Antigens
  •  go-up   go-down


23. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, Camitta B: Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. J Pediatr Hematol Oncol; 2008 May;30(5):353-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study.
  • At concentrations >0.1 mM, hydroxyurea (HU) enhances the accumulation of cytosine arabinoside (ara-C) in leukemia cells in vitro.
  • This study of children with refractory acute leukemia was designed to take advantage of this biochemical modulation.
  • Thirty-three children [26 acute lymphocytic leukemia (ALL), 7 acute nonlymphocytic leukemia] were treated; 29 received at least 1 full course.
  • There were 6 complete responses (5 ALL), 5 partial responses (3 ALL), and 19 patients with no response or progressive disease.
  • This combination of HU and ara-C is tolerable and has efficacy in refractory leukemias.
  • [MeSH-major] Cytarabine / toxicity. Hydroxyurea / toxicity. Leukemia / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Infection / epidemiology. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / mortality. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / mortality. Liver / drug effects. Liver / pathology. Skin / drug effects. Skin / pathology. Survival Analysis

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458568.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; X6Q56QN5QC / Hydroxyurea
  • [Other-IDs] NLM/ NIHMS721202; NLM/ PMC4601800
  •  go-up   go-down


24. Berköz M, Yalin S: Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility. Leuk Res; 2009 Jul;33(7):919-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of CYP2B6 G15631T polymorphism with acute leukemia susceptibility.
  • In this study, we aimed to determine whether any association exists between genetic polymorphism in CYP2B6G15631T and individual susceptibility to acute leukemia.
  • Our study group consisted of 80 acute leukemia patients and 100 unrelated healthy volunteers as a control group.
  • 44 of the acute leukemia patients were diagnosed with acute lymphoblastic leukemia (ALL) and 36 patients with acute myeloid leukemia (AML).
  • The frequencies of GG genotype (wild type) were 40.9%, 50% and 67% in ALL, AML and control groups, respectively.
  • The TT genotype (homozygous variant) was not observed in either control or leukemia cases.
  • Logistic regression analyses showed a significant correlation between the CYP2B6 G15631T polymorphism (GT) and acute leukemia patients (OR=2.481, 95% CI=1.353-4.551, p=0.003).
  • Our findings indicate that GT genotype may be an important genetic determinant for acute leukemias.
  • According to our knowledge, this is the first report of an association between acute leukemia cases and the CYP2B6 G15631T polymorphism.
  • [MeSH-major] Aryl Hydrocarbon Hydroxylases / genetics. Leukemia, Myeloid, Acute / genetics. Oxidoreductases, N-Demethylating / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Cytochrome P-450 CYP2B6. DNA, Neoplasm / genetics. Disease Susceptibility. Genotype. Humans. Middle Aged. Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144407.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  •  go-up   go-down


25. Bacher U, Kohlmann A, Haferlach T: Current status of gene expression profiling in the diagnosis and management of acute leukaemia. Br J Haematol; 2009 Jun;145(5):555-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
  • Gene expression profiling (GEP) enables the simultaneous investigation of the expression of tens of thousands of genes and was successfully introduced in leukaemia research a decade ago.
  • Aiming to better understand the diversity of genetic aberrations in acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL), pioneer studies investigated and confirmed the predictability of many cytogenetic and molecular subclasses in AML and ALL.
  • In addition, GEP can define new prognostic subclasses within distinct leukaemia subgroups, as illustrated in AML with normal karyotype.
  • Finally, GEP might enable the detection of new molecular targets for therapy in patients with acute leukaemia.
  • Meanwhile, large multicentre studies, e.g. the Microarray Innovations in LEukaemia (MILE) study, prepare for a standardised introduction of GEP in leukaemia diagnostic algorithms, aiming to translate this novel methodology into clinical routine for the benefit of patients with the complex disorders of AML and ALL.
  • [MeSH-major] Gene Expression Profiling / methods. Leukemia / diagnosis. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Gene Expression. Gene Rearrangement. Humans. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19344393.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 118
  •  go-up   go-down


26. Sancho JM, Morgades M, Arranz R, Fernández-Abellán P, Deben G, Alonso N, Blanes M, Rodríguez MJ, Nicolás C, Sánchez E, Fernández de Sevilla A, Conde E, Ribera JM, QUIT Study (PETHEMA, GELTAMO and GOTEL Groups): Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study. Med Clin (Barc); 2008 Oct 4;131(11):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.
  • BACKGROUND AND OBJECTIVE: Central nervous system (CNS) involvement in patients diagnosed with acute leukemias (AL) is an uncommon complication with poor prognosis.
  • For acute lymphoblastic leukemia patients (n = 158), CNS therapy was given to 12 cases (10 at diagnosis and 2 at relapse) and consisted of triple intrathecal therapy (TIT, methotrexate, cytarabine and hydrocortisone) in 11 and liposomal depot cytarabine in one.
  • In acute myeloblastic leukemia patients (n = 107), CNS therapy was administered to 17 cases (9 at diagnosis and 8 at relapse).
  • [MeSH-major] Central Nervous System Neoplasms / prevention & control. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Registries

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18928719.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antimetabolites, Antineoplastic; 0 / Liposomes; 04079A1RDZ / Cytarabine; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Szpecht D, Derwich K, Wachowiak J, Konatkowska B, Dworacki G: [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl]. Med Wieku Rozwoj; 2008 Oct-Dec;12(4 Pt 2):1041-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lineage switch - conversion of acute lymphoblastic leukaemia to acute myeloid leukaemia in 4 years old girl].
  • We report a case of a 4-year-old girl with diagnosed proB acute lymphoblastic leukaemia with co-expression CD33 antigen, treated according to Acute Lymphoblastic Leukaemia Intercontinental - Berlin Frankfurt Münster 2002 (ALL-IC BFM 2002) protocol for standard risk group.
  • The late isolated bone marrow relapse of acute myeloid leukaemia, type 7 was noted in our patient.
  • We recognized this case as a lineage switch acute lymphoblastic leukaemia to acute myeloid leukaemia.
  • In spite of Ida Flag regimen and following Acute Myeloid Leukaemia - Berlin Frankfurt Münster 2004 (AML-BFM 2004) protocol were administered, the clinical and haematological remission was not achieved and the patient died because of disease progression (circulatory and respiratory insufficiency).
  • [MeSH-major] Bone Marrow / pathology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / therapeutic use. Cell Lineage. Cell Transformation, Neoplastic. Child, Preschool. Daunorubicin / therapeutic use. Disease Progression. Fatal Outcome. Female. Humans. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531823.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


28. Blalock WL, Bavelloni A, Piazzi M, Faenza I, Cocco L: A role for PKR in hematologic malignancies. J Cell Physiol; 2010 Jun;223(3):572-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a subset of myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia contain low levels of PKR expression and activity, elevated PKR activity and/or expression have been detected in a wide range of hematologic malignancies, from bone marrow failure disorders to acute leukemia.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20232306.001).
  • [ISSN] 1097-4652
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / eIF-2 Kinase
  •  go-up   go-down


29. Chen XW, Yue LJ, Li CG, Li CR, Zhang M, Shi HS: [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Apr;11(4):251-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polymorphisms of thymidylate synthase gene detected by RT-PCR-denaturing gradient gel electrophoresis in children with acute leukemia].
  • This study investigated the allelic frequencies and distribution characters of single-nucleotide polymorphisms within the coding region (cSNPs) of TS gene in Chinese children with acute leukemia (AL) and normal control children in order to explore the possible relationship between the cSNP in human TS gene and chemotherapeutic effects of 5-fluorouracils.
  • [MeSH-major] Leukemia / genetics. Polymorphism, Single Nucleotide. Reverse Transcriptase Polymerase Chain Reaction / methods. Thymidylate Synthase / genetics
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Electrophoresis, Polyacrylamide Gel. Female. Humans. Infant. Infant, Newborn. Male. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374805.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


30. Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, Xu X, Li Y, Christiani DC, Kaohsiung Leukemia Research Group: Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC Cancer; 2009 Jan 13;9:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study.
  • This study investigated whether consumed cured/smoked meat and fish, the major dietary resource for exposure to nitrites and nitrosamines, is associated with childhood acute leukemia.
  • 145 acute leukemia cases and 370 age- and sex-matched controls were recruited between 1997 and 2005.
  • RESULTS: Consumption of cured/smoked meat and fish more than once a week was associated with an increased risk of acute leukemia (OR = 1.74; 95% CI: 1.15-2.64).
  • No statistically significant association was observed between leukemia risk and the consumption of pickled vegetables, fruits, and tea.
  • CONCLUSION: Dietary exposure to cured/smoked meat and fish may be associated with leukemia risk through their contents of nitrites and nitrosamines among children and adolescents, and intake of vegetables and soy-bean curd may be protective.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:79-82 [12505288.001]
  • [Cites] Comp Biochem Physiol A Comp Physiol. 1989;93(1):285-90 [2568231.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5111-7 [2548712.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):541-6 [1672382.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):139-46 [8461864.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):195-202 [8167267.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):790S-797S [7533831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):901-6 [8922298.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Radiat Environ Biophys. 1998 Feb;36(4):217-28 [9523337.001]
  • [Cites] Cancer Causes Control. 1998 Dec;9(6):553-7 [10189040.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):163-5 [15540221.001]
  • [Cites] Free Radic Biol Med. 2005 Jul 15;39(2):257-65 [15964517.001]
  • [Cites] Nutr Cancer. 2006;54(1):111-42 [16800779.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Nutr Cancer. 2006;56(2):225-31 [17474869.001]
  • [Cites] J Nutr. 2008 Apr;138(4):775-81 [18356334.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):984-90 [18339682.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • [Cites] Am J Epidemiol. 1999 Nov 1;150(9):930-8 [10547138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8 [12869409.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):667-71 [15158086.001]
  • [Cites] Free Radic Biol Med. 2004 Jun 15;36(12):1505-16 [15182853.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Ann N Y Acad Sci. 1980;355:267-79 [6940481.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(1):7-10 [3903369.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):603-9 [10797279.001]
  • [Cites] J Nutr. 2000 Aug;130(8):1887-93 [10917898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1051-8 [11045787.001]
  • [Cites] Free Radic Res. 2001 Sep;35(3):215-31 [11697121.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):777-81 [12163333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):815-21 [12223424.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Mar;24(3):403-11 [3383943.001]
  • (PMID = 19144145.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00002; United States / NIEHS NIH HHS / ES / ES09723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653540
  • [Investigator] Chang TT; Lin SF; Chiou SS; Jang RC; Hsiao HH; Liu TC; Lin PC; Hsiao CC; Sheen JM; Kuo CY; Wang MC; Huang CH; Huang CB; Wong YC; Wu HB; Lin SJ; Sun YM; Hsieh KS; Chang YH
  •  go-up   go-down


31. Rossbach HC: Diagnostic pitfalls in acute leukemia. Fetal Pediatr Pathol; 2009;28(2):69-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic pitfalls in acute leukemia.
  • In most children presenting with the common signs and symptoms of leukemia, the diagnosis is readily made.
  • However, unusual features of the disease and the absence of abnormalities on the complete blood count may render the diagnosis problematic, especially if this malignancy is not suspected.
  • The current report focuses on the unusual presentation of leukemia and the difficulties in the diagnosis of the malignancy.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Bone Marrow Cells / pathology. Child. Humans. Liver / pathology. Skin Diseases / etiology. Spinal Cord Compression / etiology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241238.001).
  • [ISSN] 1551-3823
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Golembe TJ, Yong J, Battle DJ, Feng W, Wan L, Dreyfuss G: Lymphotropic Herpesvirus saimiri uses the SMN complex to assemble Sm cores on its small RNAs. Mol Cell Biol; 2005 Jan;25(2):602-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymphotropic Herpesvirus saimiri (HVS) causes acute leukemia, T-cell lymphoma, and death in New World monkeys.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5631-6 [11714716.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1023-9 [9323130.001]
  • [Cites] EMBO J. 2002 Mar 1;21(5):1188-96 [11867547.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):8243-7 [11756452.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):720-8 [11914277.001]
  • [Cites] Semin Pediatr Neurol. 2002 Jun;9(2):145-50 [12138998.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31957-62 [12065586.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5853-63 [12411503.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1775-9 [12459587.001]
  • [Cites] Curr Neurol Neurosci Rep. 2004 Jan;4(1):74-80 [14683633.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2747-56 [15024064.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4522-33 [15121869.001]
  • [Cites] EMBO J. 1982;1(10):1259-65 [6202507.001]
  • [Cites] Hum Mol Genet. 1999 Dec;8(13):2351-7 [10556282.001]
  • [Cites] J Virol. 1999 Dec;73(12):10551-5 [10559377.001]
  • [Cites] J Cell Biol. 1999 Dec 13;147(6):1181-94 [10601333.001]
  • [Cites] J Virol. 2000 Jan;74(2):1033-7 [10623770.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1177-86 [10725331.001]
  • [Cites] Hum Mol Genet. 2000 Aug 12;9(13):1977-86 [10942426.001]
  • [Cites] J Biol Chem. 2000 Aug 25;275(34):26370-5 [10851237.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):75-85 [11149922.001]
  • [Cites] Nature. 2001 Jan 25;409(6819):539-42 [11206553.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9599-605 [11121410.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2001 Apr 29;356(1408):545-67 [11313011.001]
  • [Cites] Curr Opin Cell Biol. 2001 Jun;13(3):290-301 [11343899.001]
  • [Cites] Biochem Soc Trans. 2001 May;29(Pt 2):15-26 [11356120.001]
  • [Cites] Mol Cell. 2001 May;7(5):1111-7 [11389857.001]
  • [Cites] Curr Biol. 2001 Jul 24;11(14):1079-88 [11509230.001]
  • [Cites] EMBO J. 2001 Oct 1;20(19):5443-52 [11574476.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38645-51 [11509571.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8289-300 [11713266.001]
  • [Cites] Nat Cell Biol. 2001 Nov;3(11):945-9 [11715014.001]
  • [Cites] Curr Biol. 2001 Dec 11;11(24):1990-4 [11747828.001]
  • [Cites] EMBO J. 1986 Jul;5(7):1625-32 [2427336.001]
  • [Cites] Cell. 1988 Aug 26;54(5):599-607 [2842058.001]
  • [Cites] Nucleic Acids Res. 1989 Feb 11;17(3):1258 [2537954.001]
  • [Cites] J Virol. 1989 Aug;63(8):3307-14 [2545905.001]
  • [Cites] Virology. 1990 Jun;176(2):505-14 [2161148.001]
  • [Cites] Mol Biol Rep. 1990;14(2-3):183-92 [2141907.001]
  • [Cites] J Virol. 1990 Aug;64(8):3905-15 [2164602.001]
  • [Cites] Nucleic Acids Res. 1990 Nov 11;18(21):6456 [2173833.001]
  • [Cites] Biochim Biophys Acta. 1990 Nov 30;1087(3):265-92 [2147394.001]
  • [Cites] Nucleic Acids Res. 1991 May 25;19(10):2785 [1645866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1296-300 [1311093.001]
  • [Cites] Nucleic Acids Res. 1992 Apr 11;20(7):1810 [1315960.001]
  • [Cites] J Cell Biol. 1993 May;121(4):715-27 [8491767.001]
  • [Cites] Cell. 1995 Jan 13;80(1):155-65 [7813012.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3555-65 [8670859.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):265-9 [9207792.001]
  • [Cites] Neurobiol Dis. 1996 Apr;3(2):97-110 [9173917.001]
  • [Cites] Hum Mol Genet. 1997 Aug;6(8):1205-14 [9259265.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1013-21 [9323129.001]
  • [Cites] Cell. 1998 Nov 25;95(5):615-24 [9845364.001]
  • [Cites] Cell. 1999 Feb 5;96(3):375-87 [10025403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11167-72 [10500148.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):7540-5 [11748230.001]
  • (PMID = 15632062.001).
  • [ISSN] 0270-7306
  • [Journal-full-title] Molecular and cellular biology
  • [ISO-abbreviation] Mol. Cell. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein; 0 / GEMIN2 protein, human; 0 / Multiprotein Complexes; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / RNA, Small Nuclear; 0 / RNA-Binding Proteins; 0 / Recombinant Fusion Proteins; 0 / Ribonucleoproteins, Small Nuclear; 0 / SMN Complex Proteins
  • [Other-IDs] NLM/ PMC543424
  •  go-up   go-down


33. Lefèvre Y, Ceroni D, Läedermann A, de Rosa V, de Coulon G, Ayse HO, Kaelin A: Pediatric leukemia revealed by a limping episode: a report of four cases. Orthop Traumatol Surg Res; 2009 Feb;95(1):77-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric leukemia revealed by a limping episode: a report of four cases.
  • Acute limping in children is a common reason for consultation in pediatric emergency units.
  • Acute leukemia is a rarely encountered disease in the orthopedic surgeon's activity.
  • We report our experience with four cases of children initially seen in the pediatric emergency department for limping, as their revealing presentation of acute leukemia.
  • The physician in charge should remember that paraclinical work-up normal results do not exclude a diagnosis of acute leukemia, that any drop in hematopoietic cell counts should call for a myelogram and that paraclinical exams, including the hemogram, should be repeated until a diagnosis and improvement or confirmed cure is achieved over time.
  • [MeSH-major] Mobility Limitation. Pain / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251241.001).
  • [ISSN] 1877-0568
  • [Journal-full-title] Orthopaedics & traumatology, surgery & research : OTSR
  • [ISO-abbreviation] Orthop Traumatol Surg Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [General-notes] NLM/ Original DateCompleted: 20090708
  •  go-up   go-down


34. Sirulnik LA, Stone RM: Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease. Clin Adv Hematol Oncol; 2005 May;3(5):391-7, 429
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promyelocytic leukemia: current strategies for the treatment of newly diagnosed disease.
  • Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia that comprises about 10% of cases.
  • Current treatment strategies with ATRA and anthracycline-based chemotherapy has dramatically transformed APL into the most curable of all acute leukemias.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167012.001).
  • [ISSN] 1543-0790
  • [Journal-full-title] Clinical advances in hematology & oncology : H&O
  • [ISO-abbreviation] Clin Adv Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 69
  •  go-up   go-down


35. Bow EJ: Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes. Semin Hematol; 2009 Jul;46(3):259-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes.
  • Recrudescent neutropenic fevers, defined by the appearance of a new fever after defervescence of the first fever, are often a function of invasive fungal infection or gram-positive infections outside the spectrum of the initial empirical antibacterial regimen.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Fever / etiology. Leukemia / drug therapy. Myelodysplastic Syndromes / drug therapy. Neutropenia / etiology


36. Bacigalupo A, Lamparelli T, Gualandi F, Occhini D, Bregante S, Raiola AM, Ibatici A, di Grazia C, Dominietto A, Piaggio G, Podesta M, Bruno B, Lombardi A, Frassoni F, Viscoli C, Sacchi N, Van Lint MT: Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome. Bone Marrow Transplant; 2007 Mar;39(6):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome.
  • We assessed the long-term outcome of patients with relapsed acute myeloid (n=86) or acute lymphoid leukemia (n=66), undergoing an allogeneic hemopoietic stem cell transplantation in our unit.
  • The median blast count in the marrow was 30%.
  • The donor was a matched donor (n=132) or a family mismatched donor (n=20).
  • Twenty-two patients (15%) survive disease free, with a median follow-up of 14 years: 18 are off medications.
  • In multivariate analysis of survival, favorable predictors were chronic graft-versus-host disease (GvHD) (P=0.0003), donor other than family mismatched (P=0.02), donor age less than 34 years (P=0.02) and blast count less than 30% (P=0.07).
  • This study confirms that a fraction of relapsed leukemias is cured with an allogeneic transplant: selection of patients with a blast count <30%, identification of young, human leukocyte antigen-matched donors and the use of total body radiation may significantly improve the outcome.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid / therapy. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Bone Marrow Examination. Child. Female. Follow-Up Studies. Graft Survival. Graft vs Host Disease. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Patient Selection. Prognosis. Survivors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277788.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E, Sugiyama H: Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia; 2005 Aug;19(8):1318-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcription factor Wilms' tumour gene 1 (WT1) is important as a prognostic marker as well as in the detection and monitoring of minimal residual disease in leukaemia and myelodysplastic syndromes.
  • Evidence has accumulated over the past decade to show that WT1 is a key molecule for tumour proliferation in a large number of human neoplasms most prominent in acute leukaemias, making it a suitable target for therapeutic strategies.
  • Based on animal results, showing safety and efficacy of immunization with WT1 peptides and protein, early clinical trials in leukaemia have recently been initiated.
  • [MeSH-minor] Animals. Genes, Wilms Tumor. Humans. Immunotherapy. Leukemia / diagnosis. Leukemia / etiology. Leukemia / therapy

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Leukemia (2005) 19, 1318--1323.
  • (PMID = 15920488.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


38. Li Y, Dai Y, Wu SL, Pei P, Cao XH, Pu DF: [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia]. Zhonghua Nei Ke Za Zhi; 2005 Aug;44(8):588-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The C46359T polymorphism of DNMT3B promoter gene and pathogenesis of acute leukemia].
  • OBJECTIVE: To explore the relationship between the polymorphism of C46359T in DNMT3B promoter and the pathogenesis of acute leukemia (AL).
  • Compared with TT homozygote, CT heterozygote had a 4.669-fold increased risk of acute leukemia (OR = 4.669; 95% confidence interval 1.700-14.747).
  • [MeSH-major] DNA (Cytosine-5-)-Methyltransferase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. European Continental Ancestry Group / genetics. Female. Gene Frequency. Genotype. Humans. Male. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194411.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


39. Fernandes TA, Fukai R, Souza CA, Lorand-Metze I, Magna LA, Kraemer MH: Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. Blood Cells Mol Dis; 2010 Mar-Apr;44(2):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias.
  • We analyzed a group of 45 Brazilian individuals, 30 with acute myeloid leukemia (AML), 15 with acute lymphoid leukemia (ALL) and 100 healthy controls to assess genetic factor risk and HLA association contribution to the disease.
  • We observed significantly increased allelic distribution of HLA-DRB107 in AML patients and of HLA-DRB103 in ALL patients, which suggests that individuals in both groups are susceptible to the disease.
  • We also found significantly decreased allelic distribution of HLA-DQB104 in AML patients and of HLA-DRB104 and -DQB103 in ALL patients, which suggests protection against the disease.
  • We further found increased HLA-DRB107 and -DQB102 haplotypes in AML patients, which suggests susceptibility to the disease and decreased HLA-DRB104 and -DQB103 haplotypes in ALL patients, which also suggests protection against the disease.
  • Future studies with larger and/or multicentric samples will be required for better comprehension of the HLA role in acute leukemia pathogenesis.
  • [MeSH-major] HLA-DQ Antigens. HLA-DR Antigens. Leukemia, Lymphoid / diagnosis. Leukemia, Myeloid, Acute / diagnosis
  • [MeSH-minor] Acute Disease. Adult. Age Factors. Brazil. Female. Follow-Up Studies. Gene Frequency. Genetic Predisposition to Disease. HLA-DQ beta-Chains. HLA-DRB1 Chains. Haplotypes. Humans. Male. Sex Factors

  • MedlinePlus Health Information. consumer health - Acute Lymphocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 20051322.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DQ Antigens; 0 / HLA-DQ beta-Chains; 0 / HLA-DQB1 antigen; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains
  •  go-up   go-down


40. Staratschek-Jox A, Classen S, Gaarz A, Debey-Pascher S, Schultze JL: Blood-based transcriptomics: leukemias and beyond. Expert Rev Mol Diagn; 2009 Apr;9(3):271-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blood-based transcriptomics: leukemias and beyond.
  • In 1999, Golub et al. proposed for the first time microarray-based transcriptional profiling to be used as a new technology for the differential diagnosis of acute myeloid leukemias and acute lymphocytic leukemias.
  • This very preliminary study sparked great enthusiasm beyond the leukemias.
  • Here we highlight the advances in the field of blood transcriptomics during the last 10 years and also critically discuss the issues that need to be resolved before blood transcriptomics will become part of daily diagnostics in the leukemias, as well as in other diseases showing involvement of peripheral blood.
  • [MeSH-major] Blood. Gene Expression Profiling / methods. Leukemia / diagnosis. Leukemia / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Autoimmune Diseases / diagnosis. Autoimmune Diseases / genetics. Humans

  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379085.001).
  • [ISSN] 1744-8352
  • [Journal-full-title] Expert review of molecular diagnostics
  • [ISO-abbreviation] Expert Rev. Mol. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


41. Vannucchi AM, Guglielmelli P, Pieri L, Antonioli E, Bosi A: Treatment options for essential thrombocythemia and polycythemia vera. Expert Rev Hematol; 2009 Feb;2(1):41-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major causes of morbidity and mortality are represented by arterial and venous thrombosis, as well as by evolution to myelofibrosis or transformation to acute leukemia.
  • However, results of clinical trials with interferon, and the expected effects of novel drugs selectively targeting the abnormal pathways that are involved in the clonal myeloproliferation, are pushing therapeutic goals from disease control only to cure.

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21082994.001).
  • [ISSN] 1747-4094
  • [Journal-full-title] Expert review of hematology
  • [ISO-abbreviation] Expert Rev Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


42. Kokandakar HR, Tembhare PR, Mamoon A, Mulay VM, Bhople KS: Acute basophilic leukaemia: a case report. Indian J Pathol Microbiol; 2007 Apr;50(2):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute basophilic leukaemia: a case report.
  • Acute basophilic leukaemia is an uncommon form of acute leukaemia, rarely occurring as de novo disease.
  • Due to rarity of the disease, consistent diagnostic criteria for the identification of this entity still remain the topic of discussion.
  • We present a case of acute basophilic leukaemia with (11q23)-MLL gene rearrangement, in an 18-year-old male with review of literature and discussion of diagnostic criteria.
  • [MeSH-major] Leukemia, Basophilic, Acute / diagnosis
  • [MeSH-minor] Adolescent. Coloring Agents. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Staining and Labeling. Tolonium Chloride

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17883105.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 15XUH0X66N / Tolonium Chloride; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 11
  •  go-up   go-down


43. Hmidi K, Zaouali S, Messaoud R, Mahjoub B, Ammari W, Bacha L, Laatiri A, Jenzeri S, Khairallah M: Bilateral orbital myeloid sarcoma as initial manifestation of acute myeloid leukemia. Int Ophthalmol; 2007 Dec;27(6):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral orbital myeloid sarcoma as initial manifestation of acute myeloid leukemia.
  • BACKGROUND: Granulocytic sarcoma is a rare orbital complication of acute leukemia.
  • It concerns primarily children under 10 years of age suffering from primitive acute myeloid leukemia.
  • The diagnosis is made by clinical examination, computed tomography and confirmed by haematological investigations.
  • CASE REPORT: We report the case of a 6-year-old girl who presented with bilateral proptosis revealing acute myeloid leukemia.
  • CONCLUSION: The diagnosis of granulocytic sarcoma should be considered in any orbital mass of uncertain origin, particularly if it is bilateral.
  • Special stains and immunohistochemistry play an important role in the diagnosis.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Orbital Neoplasms / etiology. Sarcoma, Myeloid / etiology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ophthalmol. 1971 Dec;55(12):844-7 [5290915.001]
  • [Cites] Arch Dis Child. 1981 Jul;56(7):549-51 [7271290.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):466-75 [9053467.001]
  • [Cites] Radiology. 1994 Mar;190(3):698-702 [8115614.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Arch Ophthalmol. 1990 Apr;108(4):484 [2322149.001]
  • [Cites] J Pediatr Ophthalmol Strabismus. 1993 Nov-Dec;30(6):386-7 [8120745.001]
  • [Cites] Am J Ophthalmol. 2004 May;137(5):948-50 [15126169.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Mar-Apr;12 (2):255-8 [1902022.001]
  • [Cites] Can J Ophthalmol. 1975 Apr;10(2):174-83 [1055015.001]
  • [Cites] Ophthalmology. 1986 Mar;93(3):379-84 [3703507.001]
  • [Cites] Br J Ophthalmol. 1960 Jul;44:440-2 [13809445.001]
  • [Cites] Cancer. 1986 Sep 1;58(5):1101-5 [3460684.001]
  • [Cites] Arch Ophthalmol. 2003 Jan;121(1):138-42 [12523908.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Dec;19(8):597-600 [12487837.001]
  • [Cites] Cancer. 1973 Apr;31(4):948-55 [4513297.001]
  • [Cites] Radiology. 1985 Apr;155(1):167-70 [3856292.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1283-7 [9179903.001]
  • [Cites] Ophthalmologica. 1998;212(3):202-5 [9562099.001]
  • [Cites] Ophthalmology. 1983 Aug;90(8):899-905 [6195573.001]
  • [Cites] Med Pediatr Oncol. 1998 Sep;31(3):144-9 [9722895.001]
  • [Cites] J Fr Ophtalmol. 2004 Feb;27(2):184-7 [15029050.001]
  • [Cites] Acta Haematol. 1989;81(2):80-5 [2496555.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2005 Jun;25(3):195-9 [16450777.001]
  • [Cites] Am J Ophthalmol. 1979 Apr;87(4):530-2 [286549.001]
  • [Cites] Am J Ophthalmol. 1975 Dec;80(6):975-90 [1060381.001]
  • [Cites] Arch Ophthalmol. 1991 May;109 (5):734-5 [2025176.001]
  • [Cites] Eur J Haematol. 1997 Jul;59(1):1-13 [9260575.001]
  • [Cites] Br J Haematol. 1996 Mar;92(4):855-65 [8616078.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2005 Nov;69(11):1595-8 [15939484.001]
  • (PMID = 17522781.001).
  • [ISSN] 0165-5701
  • [Journal-full-title] International ophthalmology
  • [ISO-abbreviation] Int Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


44. Mayor NP, Shaw BE, Hughes DA, Maldonado-Torres H, Madrigal JA, Keshav S, Marsh SG: Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol; 2007 Sep 20;25(27):4262-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors.
  • PURPOSE: Hematopoietic stem cell transplantation (HSCT) is an important option in the management of acute leukemia, but the risk of disease relapse and death remains appreciable.
  • Recent studies have suggested that nucleotide-binding oligomerization domain 2 (NOD2)/caspase recruitment domain 15 (CARD15) gene single nucleotide polymorphisms (SNPs), implicated in innate immunity and Crohn's disease, may also affect immune function post-HSCT.
  • PATIENTS AND METHODS: NOD2/CARD15 genotypes were analyzed in 196 patients diagnosed with acute leukemia and their unrelated donors.
  • The pairs are part of a previously well-characterized cohort with a median follow-up of 2.2 years (range, 0.42 to 6.61 years).
  • T-cell depletion was used in 83% of pairs.
  • RESULTS: NOD2/CARD15 SNPs were associated with a reduction in overall survival (44% v 22%; log-rank P = .0087) due to an increase in disease relapse (32% v 54%; Gray's test P = .001) as compared with wild-type pairs.
  • The incidence of acute graft-versus-host disease was low and there was no significant difference due to the presence of SNPs.
  • CONCLUSION: These data indicate an unrecognized role for the NOD2/CARD15 gene in unrelated donor HSCT for acute leukemia.
  • The increased risk of disease relapse suggests that the wild-type gene product may contribute to a graft-versus-leukemia effect.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / therapy. Nod2 Signaling Adaptor Protein / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cohort Studies. Female. HLA Antigens / metabolism. Hematopoietic Stem Cell Transplantation. Humans. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 10;26(2):338-9; author reply 339 [18182678.001]
  • (PMID = 17724347.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0200231
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / Immunosuppressive Agents; 0 / NOD2 protein, human; 0 / Nod2 Signaling Adaptor Protein
  •  go-up   go-down


45. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood; 2008 Jan 15;111(2):566-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
  • Arsenic trioxide (ATO) induces remission in 85% of adults with refractory acute promyelocytic leukemia (APL).
  • We conducted a phase 1 trial of ATO in children (median age 13 y, range, 2-19) with refractory leukemia.
  • Patients with APL (n=13) received 0.15 mg/kg per day, and patients with other types of leukemia received 0.15 mg/kg per day (n=2) or 0.2 mg/kg per day (n=4).
  • Non-dose-limiting toxicities included elevated serum transaminases, nausea, vomiting, abdominal pain, constipation, electrolyte imbalance, hyperglycemia, dermatitis, and headache.
  • Morphologic complete response (CR) was achieved in 85% of patients with APL; no responses were observed in non-APL patients.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Arsenicals / pharmacokinetics. Leukemia, Promyelocytic, Acute / drug therapy. Lymphoma / drug therapy. Oxides / pharmacokinetics

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Leuk Lymphoma. 2004 Dec;45(12):2387-401 [15621751.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2620-5 [10893295.001]
  • [Cites] Blood. 2001 Jul 15;98(2):266-71 [11435292.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3852-60 [11559723.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Nov;58(8):521-6 [12451429.001]
  • [Cites] J Environ Sci Health A Tox Hazard Subst Environ Eng. 2003 Jan;38(1):165-83 [12635825.001]
  • [Cites] Cancer. 2003 May 1;97(9):2218-24 [12712474.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):31998-2004 [12767976.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3609-15 [14512391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83 [15070760.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35 [15044693.001]
  • [Cites] Blood. 2004 May 1;103(9):3496-502 [14701702.001]
  • [Cites] Clin Chem. 1992 Dec;38(12):2479-83 [1458588.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83 [9108090.001]
  • [Cites] Blood. 1997 May 1;89(9):3345-53 [9129041.001]
  • [Cites] Blood. 1997 May 1;89(9):3354-60 [9129042.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):124-33 [9450572.001]
  • [Cites] N Engl J Med. 1998 Nov 5;339(19):1341-8 [9801394.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3053-8 [10397243.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2102-11 [10477740.001]
  • [Cites] Blood. 2000 Jan 1;95(1):90-5 [10607690.001]
  • (PMID = 17959855.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00020111
  • [Grant] United States / NCI NIH HHS / CA / U01 CA097452; United States / NCI NIH HHS / CA / UM1 CA097452; United States / NCI NIH HHS / CA / CA97452; United States / Intramural NIH HHS / /
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Oxides; S7V92P67HO / arsenic trioxide
  • [Other-IDs] NLM/ PMC2200837
  •  go-up   go-down


46. Kahng J, Shin SY, Han K: [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation]. Korean J Lab Med; 2007 Dec;27(6):406-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Proportions of cells expressing CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, or CD13,33+/CD34+ in the regenerating bone marrows during complete remission of acute leukemia or after bone marrow transplantation].
  • We attempted to discover the proportions of undifferentiated stem cells, committed stem cells, B cell precursors, and myeloid precursors in the regenerating bone marrows during complete remission (CR) and after engraftment of BMT.
  • METHODS: Bone marrow samples from 82 patients with acute leukemia in CR and from 25 patients after BMT engraftment, along with 22 control samples, were used to find the numbers of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells in the large lymphocyte gate by flow cytometry.
  • We cross-analyzed our results in terms of groups: CR, BMT, and initial diagnosis groups.
  • RESULTS: The proportions of CD38-/CD34+, CD38+/CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells are more highly distributed in acute B-lymphoblastic leukemia than the normal group and also in the CR than the BMT group.
  • CD19+/CD34+ cells were increased in the relapse group and CD38+/ CD34+, CD19+/CD34+, and CD13,33+/CD34+ cells were increased in the group with chromosomal abnormality.
  • [MeSH-major] Antigens, CD19 / metabolism. Antigens, CD34 / metabolism. Antigens, CD38 / metabolism. Bone Marrow Transplantation. Leukemia / metabolism
  • [MeSH-minor] Acute Disease. Bone Marrow / physiology. Flow Cytometry. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / therapeutic use. Hematopoietic Stem Cells / immunology. Hematopoietic Stem Cells / metabolism. Humans. Immunophenotyping. Regeneration. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18160830.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


47. Ansari M, Krajinovic M: Pharmacogenomics of acute leukemia. Pharmacogenomics; 2007 Jul;8(7):817-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenomics of acute leukemia.
  • Leukemia exists in two different forms, myeloid and lymphoid.
  • Acute lymphoblastic leukemia more frequently occurs in children, whereas the risk of acute myeloid leukemia is more common in adults.
  • Prognosis is particularly poor in adult acute myeloid leukemia.
  • Treatment failure in childhood acute lymphoblastic leukemia due to drug resistance remains the leading cause of cancer-related death in children.
  • Here, we provide an overview of pharmacogenetics studies carried out in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia, attempting to find the associations between treatment responses and polymorphisms in the genes whose products are needed for metabolism, and effects of drugs used in the treatment of leukemia.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Pharmacogenetics
  • [MeSH-minor] Child. Humans. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240908.001).
  • [ISSN] 1744-8042
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 130
  •  go-up   go-down


48. Yegin ZA, Ozkurt ZN, Aki SZ, Sucak GT: Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation. Transfus Apher Sci; 2010 Jun;42(3):239-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.
  • Leukemia relapse is a serious therapeutic challenge following hematopoietic stem cell transplantation (HSCT).
  • A total of 15 patients (65.2%) developed acute graft versus host disease (GVHD).
  • Further strategies are required to improve the anti-tumor properties of alloreactive donor lymphocytes and to obtain durable responses with DLI in patients with relapsed acute leukemia after allogeneic HSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Neoplasm Recurrence, Local / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20385512.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


49. Osuji N, Matutes E, Morilla A, Del Giudice I, Wotherspoon A, Catovsky D: Prolonged treatment response in aggressive natural killer cell leukemia. Leuk Lymphoma; 2005 May;46(5):757-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged treatment response in aggressive natural killer cell leukemia.
  • We describe a case of natural killer (NK) cell leukemia with acute presentation, systemic symptoms and hepatosplenomegaly.
  • The uniform and aberrant phenotype of NK cells with infiltration of bone marrow and spleen was in keeping with a malignant diagnosis.
  • We discuss the difficulties in the diagnosis of this condition, explore possible causes of cytopenia(s), and highlight the role of immunosuppression in controlling disease manifestations in large granular lymphocyte proliferative disorders.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Killer Cells, Natural / pathology. Leukemia / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. PENTOSTATIN .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019515.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 395575MZO7 / Pentostatin; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


50. Buyukavci M, Olgun H, Ceviz N: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol; 2005 Apr;28(2):201-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
  • 5-HT3 receptor antagonists, including granisetron and ondansetron, are widely used in the prophylactic treatment of chemotherapy-induced nausea and vomiting.
  • The effects of intravenously infused (over 30 seconds) 0.1 mg/kg ondansetron and 40 microg/kg granisetron on ECG were assessed in 22 children receiving high-dose methotrexate therapy for acute lymphoblastic leukemia.
  • [MeSH-major] Antiemetics / pharmacology. Granisetron / pharmacology. Heart Rate / drug effects. Ondansetron / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Serotonin Antagonists / pharmacology

  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Oncol. 2005 Dec;28(6):634-5 [16317278.001]
  • (PMID = 15803017.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiemetics; 0 / Antimetabolites, Antineoplastic; 0 / Serotonin Antagonists; 4AF302ESOS / Ondansetron; WZG3J2MCOL / Granisetron; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


51. Kuliszkiewicz-Janus M, Tuz MA, Baczyński S: Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. Biochim Biophys Acta; 2005 Oct 15;1737(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia.
  • The aim of the experiment was to evaluate the changes of phospholipid concentrations in patients (n=30) with acute leukemia compared with reference group of healthy volunteers (n=21).
  • PLs of patients were assayed at least twice: at the time of diagnosis and, when appropriate, at the time of complete remission from the disease (CR).
  • At the time of diagnosis, the mean concentrations of studied compounds were: (1.602+/-0.716) mmol/l for PC+CPLAS; (0.041+/-0.048) mmol/l for LPC; (0.398+/-0.198) mmol/l for SM; (0.045+/-0.071) mmol/l for PI+PE.
  • All concentrations found in patients at the time of diagnosis were significantly lower than in reference group and in those benefited from complete remission (CR).
  • [MeSH-major] Leukemia / blood. Phospholipids / blood
  • [MeSH-minor] Acute Disease. Adult. Aged. Female. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Phosphorus Isotopes


52. Abdulsalam AH: Chemotherapeutic trial for acute leukemia in Iraq. Turk J Haematol; 2009 Dec 5;26(4):216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic trial for acute leukemia in Iraq.
  • [Transliterated title] Irak'ta akut lösemi için kemoterapötik deneme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265640.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


53. Bitner-Glindzicz M, Osei-Lah V, Colvin I, Sirimanna T, Lucas D, Mac Ardle B, Webb D, Shankar A, Kingston J, Jenkins L, Rahman S: Aminoglycoside-induced deafness during treatment of acute leukaemia. Arch Dis Child; 2010 Feb;95(2):153-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aminoglycoside-induced deafness during treatment of acute leukaemia.
  • Three unrelated children from ethnically diverse backgrounds who were treated for acute leukaemia became profoundly and irreversibly deaf during treatment.
  • Children diagnosed with acute leukaemia should be tested for this mutation at diagnosis, and alternative antibiotics chosen for the treatment of sepsis.
  • [MeSH-major] Aminoglycosides / adverse effects. Anti-Bacterial Agents / adverse effects. Deafness / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Child, Preschool. DNA, Mitochondrial / genetics. Female. Genetic Predisposition to Disease. Humans. Male. Mutation. Opportunistic Infections / drug therapy. Pedigree


54. Scolnik MP, Aranguren PN, Cuello MT, Palacios MF, Sanjurjo J, Giunta M, Bracco MM, Acevedo S: Biphenotypic acute leukemia with t(15;17). Leuk Lymphoma; 2005 Apr;46(4):607-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphenotypic acute leukemia with t(15;17).
  • Biphenotypic acute leukemias (BAL) represent 5% of all acute leukemias.
  • Here we report a BAL case, with blasts showing lymphoblast morphology and positivity for myeloperoxidase (in 6% of the blast cells).
  • This report describes a BAL case with an unfrequent cytogenetic abnormality, and highlights the importance of correlating the results of multiple diagnostic methods in order to establish a correct diagnosis and treatment in BAL patients.
  • [MeSH-major] Chromosome Inversion. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Child. Chromosome Aberrations. Chromosomes, Human, Pair 8 / genetics. Female. Flow Cytometry / methods. Gene Rearrangement. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence / methods. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trisomy

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019491.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Shiozawa K, Nakanishi T, Tan M, Fang HB, Wang WC, Edelman MJ, Carlton D, Gojo I, Sausville EA, Ross DD: Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias. Clin Cancer Res; 2009 Mar 1;15(5):1698-707
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
  • In this preclinical study, we evaluated combining cytosine arabinoside [1-beta-D-arabinofuranosylcytosine (ara-C)] and/or etoposide with vorinostat for use in the treatment of acute leukemias.
  • EXPERIMENTAL DESIGN: Cell survival was examined in vitro in HL-60 human myeloid leukemia cells and K562 myeloid blast crisis chronic myelogenous leukemia cells, using the 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and/or fluorescein diacetate/propidium iodide assays.
  • Cell cycle phase distribution was measured by flow cytometry.
  • Cell cycle analyses revealed that the sequence-dependent interaction of vorinostat and ara-C or etoposide reflected the arrest of cells in G1 or G2 phase during vorinostat treatment and recovery into S phase after removal of vorinostat.
  • CONCLUSIONS: These findings using two independent methods to assess drug combination effects provide a preclinical rationale for phase I trials of the sequential combination of vorinostat followed by ara-C and etoposide in patients with advanced or refractory leukemias.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid / drug therapy
  • [MeSH-minor] Acute Disease. Blast Crisis. Cell Survival / drug effects. Cytarabine / administration & dosage. Drug Evaluation, Preclinical. Drug Synergism. Etoposide / administration & dosage. G1 Phase / drug effects. Humans. Hydroxamic Acids / administration & dosage. S Phase / drug effects. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. Vorinostat .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223502.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA106767
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxamic Acids; 04079A1RDZ / Cytarabine; 58IFB293JI / vorinostat; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


57. Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC: Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer; 2008 Oct;47(10):884-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
  • In addition, less common aberrations (particularly gene fusions) involving JAK2 have been described in acute leukemias.
  • In this report, we identify SSBP2 as a new JAK2 fusion partner in a patient with pre-B cell acute lymphocytic leukemia.
  • [MeSH-major] Chromosomes, Human, Pair 5 / genetics. Chromosomes, Human, Pair 9 / genetics. DNA-Binding Proteins / genetics. Janus Kinase 2 / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Humans. In Situ Hybridization, Fluorescence. Male. Mutation. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618714.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01CA066996-11A1
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / SSBP2 protein, human; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


58. Zou Z, Cao X, Wang Z: [P53 abnormality and clinical prognosis of leukemia patients with complex chromosomal abnormalities]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb;27(1):81-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [P53 abnormality and clinical prognosis of leukemia patients with complex chromosomal abnormalities].
  • OBJECTIVE: To investigate the p53 deletion in leukemia patients with complex chromosomal abnormalities (CCA) and the clinical significance.
  • METHODS: The p53 deletion status of 38 leukemia cases with CCA and 24 cases without CCA were analyzed by interphase fluorescence in situ hybridization (I-FISH).
  • The rate of complete remission in 13 cases of acute leukemia with CCA was 15.4%, with median survival time (MST) of 105 days.
  • [MeSH-major] Chromosome Aberrations. Gene Deletion. Leukemia / genetics. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20140875.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


59. Takeda M, Yamaguchi S, Eguchi K, Kajiume T, Nishimura S, Kobayashi M, Kurisu K: Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report. Neurol Med Chir (Tokyo); 2009 May;49(5):221-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal epidural granulocytic sarcoma in a child precedent to clinical manifestation of acute myeloid lymphoma: case report.
  • A 13-year-old boy presented with an epidural thoracic granulocytic sarcoma manifesting as rapidly progressive paraplegia preceding clinical manifestation of acute myeloid leukemia (AML).
  • The initial histological diagnosis was malignant lymphoma.
  • The correct diagnosis of epidural granulocytic sarcoma and AML was established based on cell-surface markers and a chromosomal study of the bone marrow cells.
  • A combination of chemotherapy and bone marrow transfusion achieved complete remission of leukemia.
  • Granulocytic sarcoma should be considered in the differential diagnosis of an epidural mass in pediatric patients with or without acute leukemia.
  • Immediate diagnosis and appropriate treatment are recommended to prevent leukemic transformation.
  • [MeSH-major] Epidural Neoplasms / surgery. Leukemia, Myeloid, Acute / diagnosis. Sarcoma, Myeloid / surgery. Spinal Neoplasms / surgery

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465795.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


60. Koskenvuo M, Möttönen M, Rahiala J, Saarinen-Pihkala UM, Riikonen P, Waris M, Ziegler T, Uhari M, Ruuskanen O, Salmi TT: Mixed bacterial-viral infections in septic children with leukemia. Pediatr Infect Dis J; 2007 Dec;26(12):1133-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed bacterial-viral infections in septic children with leukemia.
  • BACKGROUND: Febrile infections in children with leukemia are common.
  • The prospective multicenter survey included 156 febrile episodes in 51 children with acute leukemia.
  • CONCLUSIONS: Our findings suggest that invasive bacterial infections are commonly associated with viral infections in children with leukemia.
  • [MeSH-major] Bacteremia / complications. Leukemia / complications. Virus Diseases / complications

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043451.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Yu F, Li CW, Wei H, Liu XP, Lin D, Gong JY, Qin S, Xu FY, Mi YC, Wang JX: [Identification of complex chromosomal aberrations in acute leukemia by using conventional cytogenetics combined with multiplex fluorescence in situ hybridization]. Zhonghua Xue Ye Xue Za Zhi; 2010 May;31(5):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Identification of complex chromosomal aberrations in acute leukemia by using conventional cytogenetics combined with multiplex fluorescence in situ hybridization].
  • OBJECTIVE: To explore the value of multiplex fluorescence in situ hybridization (M-FISH) technique in the detection of the complex chromosomal aberrations (CCAs) and marker chromosomes in acute leukemia (AL).
  • The other 29 structural abnormalities including 17 marker chromosomes were characterized by M-FISH.
  • [MeSH-minor] Chromosome Aberrations. Cytogenetics. Humans. Leukemia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122305.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


62. Kriukov AI, Karel'skaia NA: [Therapeutic and diagnostic policy in nasal bleeding in patients with acute leukemia]. Vestn Otorinolaringol; 2007;(1):37-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic and diagnostic policy in nasal bleeding in patients with acute leukemia].
  • The algorithm of the otorhinolaryngologist's actions in nasal bleeding (NB) in acute leukemia (AL) patients is presented.
  • [MeSH-major] Algorithms. Aprotinin / therapeutic use. Epistaxis. Fibrinogen / therapeutic use. Health Policy. Leukemia / diagnosis. Leukemia / epidemiology. Thrombin / therapeutic use
  • [MeSH-minor] Acute Disease. Drug Combinations. Humans. Otolaryngology / methods. Tampons, Surgical

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. APROTININ .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17495802.001).
  • [ISSN] 0042-4668
  • [Journal-full-title] Vestnik otorinolaringologii
  • [ISO-abbreviation] Vestn. Otorinolaringol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / tachocomb; 9001-32-5 / Fibrinogen; 9087-70-1 / Aprotinin; EC 3.4.21.5 / Thrombin
  • [Number-of-references] 12
  •  go-up   go-down


63. Pawelec K, Trzcińska A, Siennicka J, Malinowska I, Litwińska B: [Epstein-Barr infections in children with acute leukaemia. Preliminary report]. Med Wieku Rozwoj; 2008 Jan-Mar;12(1):485-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epstein-Barr infections in children with acute leukaemia. Preliminary report].
  • THE AIM: of this study was to evaluate the effectiveness of laboratory methods used to detect EBV and to monitor EBV infections in children with acute leukaemia.
  • MATERIALS AND METHODS: we conducted the study on 30 children with acute leukaemia.
  • The control group were 11 subjects, without chronic or neoplastic disease, undergoing routine laboratory tests in the Virology Department.
  • Results of serological investigations indicated the type of EBV infection in our patients.
  • 3. In order to assess the effectiveness of serological and molecular methods in evaluation of EBV infection type in children with acute leukaemia, it is necessary to investigate a larger group of patients and taken at least three times.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663268.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


64. Ogawa K, Noji H, Furukawa M, Harada-Shirado K, Mashimo Y, Takahashi H, Matsumoto H, Kimura S, Shichishima-Nakamura A, Ohkawara H, Ikeda K, Ohto H, Takeishi Y: Hematopoietic stem cell transplantation in the Department of Hematology, Fukushima Medical University. Fukushima J Med Sci; 2010 Dec;56(2):107-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation in the Department of Hematology, Fukushima Medical University.
  • From 1996 to the end of 2009, a total of 114 cases of hematopoietic stem cell transplantation were performed in the Department of Hematology, Fukushima Medical University.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) was performed in 37 cases of acute leukemia, 10 of myelodysplastic syndrome, 5 of aplastic anemia, and 5 others.
  • Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 34 cases of malignant lymphoma, 15 of multiple myeloma, and 8 others.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods
  • [MeSH-minor] Academic Medical Centers. Adult. Aged. Female. Humans. Japan. Leukemia / pathology. Lymphoma / pathology. Male. Middle Aged. Myelodysplastic Syndromes / pathology. Prognosis. Research Design. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21502710.001).
  • [ISSN] 2185-4610
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Ogura K, Kimura F, Kobayashi S, Torikai H, Ikeda T, Sato K, Motoyoshi K: Myeloid/NK cell precursor acute leukemia lost both CD13 and CD33 at first diagnosis. Leuk Res; 2006 Jun;30(6):761-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid/NK cell precursor acute leukemia lost both CD13 and CD33 at first diagnosis.
  • It has been reported that malignancies of natural killer (NK) cell precursors, which are present in both myeloid and lymphoid antigens, are characterized by immature lymphoblastoid morphology with CD7+, CD33+ and CD56+ phenotype.
  • Here, we report a 18-year-old man who was diagnosed with CD33- and CD13- NK cell precursor acute leukemia at first diagnosis.
  • Following a 3-year remission state, he had a relapse as a testicular tumor and CD33+ myeloid/NK cell precursor acute leukemia after allogenic BMT.
  • This case suggests that myeloid antigens are not necessary for diagnosis of myeloid/NK cell precursor acute leukemia.
  • [MeSH-major] Antigens, CD / blood. Antigens, CD13 / blood. Antigens, Differentiation, Myelomonocytic / blood. Killer Cells, Natural. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Testicular Neoplasms / blood. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140376.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD7; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


66. Smadja DM, Gisselbrecht M, Valensi F, Mossafa H, Darnige L: [Acute megakaryoblastic leukemia (AML-7) in a woman of 95 years]. Ann Biol Clin (Paris); 2006 Mar-Apr;64(2):173-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute megakaryoblastic leukemia (AML-7) in a woman of 95 years].
  • [Transliterated title] Leucémie aiguë mégacaryoblastique (LAM-7) chez une patiente de 95 ans.
  • Acute leukemia of megakaryocyte lineage (AML-7) is a rare entity defined by a blastic proliferation of which a part (>or= 50%) is represented by megakaryoblasts.
  • We report the case of a 95 year old woman presenting a AML-7 secondary to a myelodysplastic syndrome (MDS), that represents an unusual form of MDS acutisation.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / diagnosis


67. Bornhäuser M, Oelschlaegel U, Platzbecker U, Bug G, Lutterbeck K, Kiehl MG, Schetelig J, Kiani A, Illmer T, Schaich M, Theuser C, Mohr B, Brendel C, Fauser AA, Klein S, Martin H, Ehninger G, Thiede C: Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica; 2009 Nov;94(11):1613-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.
  • Analysis of donor chimerism is an important diagnostic tool to assess the risk of relapse after allogeneic stem cell transplantation, especially in patients lacking a specific marker suitable for monitoring of minimal residual disease.
  • We prospectively investigated the predictive value of donor chimerism analyses in sorted CD34(+) peripheral blood cells in 90 patients with acute leukemia and myelodysplastic syndrome.
  • Monitoring of CD34(+) donor chimerism in the peripheral blood allows prediction of imminent relapse after allogeneic stem cell transplantation even when a disease-specific marker is lacking.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Neoplasm, Residual / diagnosis. Transplantation Chimera
  • [MeSH-minor] Antigens, CD34. Humans. Leukemia / diagnosis. Leukemia / mortality. Molecular Diagnostic Techniques. Prospective Studies. Recurrence. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1976-85 [11753621.001]
  • [Cites] Br J Haematol. 1991 Oct;79(2):218-25 [1958479.001]
  • [Cites] Stat Med. 1997 Apr 30;16(8):901-10 [9160487.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3582-90 [9808551.001]
  • [Cites] Bone Marrow Transplant. 1999 May;23(10):1055-60 [10373073.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2048-50 [15470491.001]
  • [Cites] Blood. 2005 Jan 1;105(1):54-60 [15345597.001]
  • [Cites] Leukemia. 2005 May;19(5):814-21 [15772700.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5675-87 [16110027.001]
  • [Cites] Leuk Res. 2007 Feb;31(2):257-9 [16620971.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1379-87 [17488876.001]
  • [Cites] Leukemia. 2007 Sep;21(9):1907-14 [17611565.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2384-5 [17581611.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):4-16 [18000811.001]
  • [Cites] Exp Hematol. 2009 Jan;37(1):135-42 [19100523.001]
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Ann Hematol. 2001 Mar;80(3):144-9 [11320898.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1430-3 [15201854.001]
  • (PMID = 19880783.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD34
  • [Other-IDs] NLM/ PMC2770975
  •  go-up   go-down


68. Béné MC: Immunophenotyping of acute leukaemias. Immunol Lett; 2005 Apr 15;98(1):9-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotyping of acute leukaemias.
  • Progress in the management and understanding of acute leukaemia can only be obtained if these diseases are thoroughly investigated, both clinically and with a series of biological tools.
  • Among the variety of approaches of acute leukaemia definition, immunophenotyping has taken over the past 25 years a predominant and now well-defined place, although room is left for further improvement.
  • In this review, the current state-of-the-art of immunophenotyping of acute leukaemias will be replaced in the context of physiological leukocyte maturation.
  • [MeSH-major] Immunophenotyping. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Animals. Antigens, Differentiation, B-Lymphocyte / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. B-Lymphocytes / immunology. B-Lymphocytes / pathology. Cell Lineage / immunology. Humans. Myeloid Cells / immunology. Myeloid Cells / pathology. T-Lymphocytes / immunology. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790504.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Differentiation, T-Lymphocyte
  • [Number-of-references] 62
  •  go-up   go-down


69. Ravandi F, Kebriaei P: Cytokines in the treatment of acute leukemias. Cancer Treat Res; 2005;126:313-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines in the treatment of acute leukemias.
  • [MeSH-major] Cytokines / therapeutic use. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209072.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 88
  •  go-up   go-down


70. Thomas X, Cannas G, Chelghoum Y: [Special issues related to the treatment of acute leukemias in women]. Bull Cancer; 2010 Aug;97(8):1011-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Special issues related to the treatment of acute leukemias in women].
  • The treatment of acute leukemia is usually similar in women and men.
  • However, diagnosis in women poses additional challenges in clinical practice such as leukemia following breast or ovarian cancers, prevention of abnormal uterine bleeding in premenopausal females, treatment during pregnancy related-problems in long-term survivors.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Neoplasms, Second Primary / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / adverse effects. Breast Neoplasms / therapy. Female. Fertility / drug effects. Fertility / radiation effects. Humans. Ovarian Neoplasms / therapy. Ovary / drug effects. Pregnancy. Pregnancy Complications, Neoplastic / etiology. Pregnancy Complications, Neoplastic / therapy. Puberty, Delayed / chemically induced. Sex Factors. Uterine Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20435579.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 154
  •  go-up   go-down


71. Johny A, Song KW, Nantel SH, Lavoie JC, Toze CL, Hogge DE, Forrest DL, Sutherland HJ, Le A, Nitta JY, Barnett MJ, Smith CA, Shepherd JD, Nevill TJ: Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide. Biol Blood Marrow Transplant; 2006 Apr;12(4):480-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
  • Primary refractory acute leukemia (AL) has a poor prognosis, although some patients can be salvaged with allogeneic stem cell transplantation (SCT).
  • Forty-two patients had acute myelogenous leukemia (AML), 13 patients had acute lymphoblastic leukemia (ALL), and 4 patients had acute biphenotypic leukemia.
  • CR1 rates were similar in AML (54%) and ALL/acute biphenotypic leukemia (67%; P = .52), and analysis of baseline characteristics did not reveal any predictors of response to VP/Cy.
  • In the allogeneic SCT group, 5-year EFS was 52% for AML patients and 14% for ALL patients (P = .04), and only male sex was predictive of a favorable outcome (P = .03).
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Leukemia / mortality. Salvage Therapy / mortality. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545732.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


72. Serefhanoglu S, Buyukasik Y, Goker H, Sayinalp N, Ozcebe OI: Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series. J Natl Med Assoc; 2009 Mar;101(3):270-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphenotypic acute leukemia treated with acute myeloid leukemia regimens: a case series.
  • This study retrospectively analyzed 8 cases of biphenotypic acute leukemia (BAL) in respect of morphology, immune phenotype, karyotype, and clinical manifestations.
  • Because selection of an antileukemic chemotherapy regimen for acute leukemia is largely based on whether a case is classified as myeloid or lymphoid, the presence of markers for both lineages may have important implications for treatment.
  • All of our patients were treated with regimens designed for acute myeloid leukemia (AML).
  • Consequently, 6 out of 8 BAL patients achieved complete remission with AML-type regimens.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Biomarkers. Case-Control Studies. Cytarabine / therapeutic use. Female. Humans. Idarubicin / therapeutic use. Immunophenotyping. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / physiopathology. Male. Middle Aged. Mitoxantrone / therapeutic use. Retrospective Studies

  • Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19331261.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biomarkers; 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; ZRP63D75JW / Idarubicin
  •  go-up   go-down


73. Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J: Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem; 2008 Nov;41(16-17):1377-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias.
  • OBJECTIVE: We evaluated whether the proteasomal chymotrypsin-like (ChT-L) activity is increased in plasma of patients with acute lymphoblastic (ALL), acute myeloblastic (AML) and chronic lymphocytic (CLL) leukemias.
  • RESULTS: The activity was significantly (P<0.001) higher in the plasma of ALL and AML patients at the diagnosis than in healthy subjects and decreased after therapy or remained unchanged or rose during relapse.
  • By contrast, in CLL patients at the diagnosis, the activity did not differ significantly from the healthy controls.
  • CONCLUSIONS: Plasma proteasome ChT-L activity can be a useful bio-marker for patients with acute leukemia at the blast stage.
  • [MeSH-major] Chymotrypsin / blood. Leukemia / blood. Proteasome Endopeptidase Complex / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Hydrolysis / drug effects. L-Lactate Dehydrogenase / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Male. Middle Aged. Oligopeptides / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proteasome Inhibitors. Protein Subunits / metabolism. Sodium Dodecyl Sulfate / pharmacology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773885.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Proteasome Inhibitors; 0 / Protein Subunits; 134381-21-8 / epoxomicin; 368GB5141J / Sodium Dodecyl Sulfate; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.21.1 / Chymotrypsin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


74. Finazzi G, Barbui T: The treatment of polycythaemia vera: an update in the JAK2 era. Intern Emerg Med; 2007 Mar;2(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelosuppressive drugs can reduce the rate of thrombosis, but there is concern that their use raises the risk of transformation into acute leukaemia.
  • The recent discovery of JAK2 V617F mutation in the vast majority of polycythaemia vera patients opens new avenues for the treatment of this disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Hematol. 2000 Mar;79(3):103-9 [10803930.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3589-93 [10828048.001]
  • [Cites] Br J Haematol. 2000 Sep;110(3):577-83 [10997967.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1144-9 [11830459.001]
  • [Cites] Curr Hematol Rep. 2003 May;2(3):257-63 [12901348.001]
  • [Cites] N Engl J Med. 2004 Jan 8;350(2):114-24 [14711910.001]
  • [Cites] Lancet. 1978 Dec 9;2(8102):1219-22 [82733.001]
  • [Cites] Semin Hematol. 1986 Apr;23(2):132-43 [3704665.001]
  • [Cites] Semin Hematol. 1986 Jul;23(3):172-6 [3749927.001]
  • [Cites] Ann Intern Med. 1993 Dec 1;119(11):1091-2 [8239228.001]
  • [Cites] Am J Hematol. 1996 May;52(1):42-6 [8638610.001]
  • [Cites] Semin Hematol. 1997 Jan;34(1):17-23 [9025158.001]
  • [Cites] Blood. 1998 Jan 15;91(2):616-22 [9427717.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1205-13 [9740087.001]
  • [Cites] Eur J Haematol. 1999 Jan;62(1):27-31 [9918308.001]
  • [Cites] Br J Haematol. 1999 Mar;104(3):438-41 [10086775.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2664-70 [15585653.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2224-32 [15710945.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] J Biol Chem. 2005 Jun 17;280(24):22788-92 [15863514.001]
  • [Cites] Blood Rev. 2005 Sep;19(5):243-52 [15963833.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2162-8 [15920007.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):259-65 [16210039.001]
  • [Cites] N Engl J Med. 2005 Dec 1;353(22):2373-83 [16319386.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3339-41 [16352805.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4214-22 [16484586.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):451-8 [16804923.001]
  • [Cites] Blood. 2006 Sep 15;108(6):2037-40 [16709929.001]
  • [CommentIn] Intern Emerg Med. 2007 Jun;2(2):147 [17634823.001]
  • (PMID = 17551678.001).
  • [ISSN] 1828-0447
  • [Journal-full-title] Internal and emergency medicine
  • [ISO-abbreviation] Intern Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 33
  • [Other-IDs] NLM/ PMC2780604
  •  go-up   go-down


76. Forestier E, Schmiegelow K, Nordic Society of Paediatric Haematology and Oncology NOPHO: The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations. J Pediatr Hematol Oncol; 2006 Aug;28(8):486-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations.
  • The correlation between age and karyotype was studied in 1425, 0 to 14.9 years old children who were diagnosed with acute lymphoblastic leukemia (ALL) or acute myeloblastic leukemia.
  • Almost 80% of the non-Down B-cell precursor ALL cases in the 2 to 7 years frequency peak group who had aberrant cytogenetic results had either a high-hyperdiploid clone (51 to 61 chromosomes) or a translocation t(12;21)(p13;q22).
  • Among B-cell precursor ALL cases, high white blood cell counts correlated with earlier age at diagnosis (rS=-0.23; P<0.001) being most evident for 11q23/MLL-aberrations, translocation t(12;21)(p13;q22), and high-hyperdiploidy.
  • Among acute myeloblastic leukemia patients, frequency peaks were found for those with MLL/11q23 rearrangements (peak: first year), Down syndrome (peak: second to third year), or cytogenetic abnormalities other than translocations t(8;21), t(15;17), and inv(16)/t(16;16) (peak: first to third year).
  • The epidemiology of the cytogenetic subsets of acute leukemias questions whether age as a disease-related prognostic parameter has any relevance in childhood leukemia clinical research beyond being a surrogate marker for more important, truly biologic features such as cytogenetic aberrations and white cell count at diagnosis.
  • Further research is needed to explore whether the 2 to 7 years age incidence peak in childhood ALL harbor yet unidentified cytogenetic subsets with the same natural history as the high-hyperdiploid and t(12;21)-positive leukemias.
  • [MeSH-major] Chromosome Aberrations. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Age Distribution. Child. Child, Preschool. Cohort Studies. Comorbidity. Cytogenetic Analysis / methods. Down Syndrome / diagnosis. Down Syndrome / epidemiology. Down Syndrome / genetics. Female. Humans. Incidence. Infant. Infant, Newborn. Karyotyping. Male. Ploidies. Recurrence. Registries / statistics & numerical data. Risk Factors. Scandinavian and Nordic Countries / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912588.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


77. Mohren M, Markmann I, Jentsch-Ullrich K, Koenigsmann M, Lutze G, Franke A: Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer; 2006 Jan 30;94(2):200-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of venous thromboembolism in patients with acute leukaemia.
  • Patients with malignancies have an increased risk for venous thromboembolisms (VTE), but data on patients with acute leukaemia are very limited so far.
  • We found VTE in 12% of 455 patients with acute leukaemia, half of which occurred in association with central venous catheters, with equal risk of ALL and AML.
  • [MeSH-major] Leukemia / complications. Venous Thrombosis / epidemiology. Venous Thrombosis / etiology

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] J Thromb Haemost. 2005 Sep;3(9):1985-92 [16102104.001]
  • [Cites] Am J Hematol. 2003 Jan;72(1):43-52 [12508268.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • [Cites] Leuk Lymphoma. 2003 Sep;44(9):1495-501 [14565650.001]
  • [Cites] Arch Intern Med. 2004 Jan 26;164(2):190-4 [14744843.001]
  • [Cites] J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):21-31 [14760208.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):92-5 [15226761.001]
  • [Cites] N Engl J Med. 1992 Oct 15;327(16):1128-33 [1528208.001]
  • [Cites] N Engl J Med. 1998 Apr 23;338(17):1169-73 [9554856.001]
  • [Cites] Lancet. 1998 Apr 11;351(9109):1077-80 [9660575.001]
  • [Cites] Thromb Res. 2005;115(1-2):59-64 [15567454.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1349-51 [15798767.001]
  • [Cites] Thromb Res. 2005;116(2):109-14 [15907524.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):811-7 [15953009.001]
  • [Cites] Arch Intern Med. 2005 Aug 8-22;165(15):1782-7 [16087828.001]
  • [Cites] Thromb Haemost. 2002 Apr;87(4):575-9 [12008937.001]
  • (PMID = 16421591.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361116
  •  go-up   go-down


78. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, de la Cámara R, Weisser M, Liakopoulou E, Abecasis M, Heussel CP, Pineau M, Ljungman P, Einsele H, Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group, Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation: Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica; 2010 Oct;95(10):1762-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study.
  • BACKGROUND: Recurrence of prior invasive fungal infection (relapse rate of 30-50%) limits the success of stem cell transplantation.
  • Secondary prophylaxis could reduce disease burden and improve survival.
  • DESIGN AND METHODS: A prospective, open-label, multicenter trial was conducted evaluating voriconazole (4 mg/kg/12 h intravenously or 200 mg/12 h orally) as secondary antifungal prophylaxis in allogeneic stem cell transplant recipients with previous proven or probable invasive fungal infection.
  • RESULTS: Forty-five patients were enrolled, 41 of whom had acute leukemia.
  • Eleven patients (24%) died within 12 months of transplantation, but only one due to systemic fungal disease.
  • The 1-year cumulative incidence of invasive fungal disease was 6.7±3.6%.
  • CONCLUSIONS: Voriconazole appears to be safe and effective for secondary prophylaxis of systemic fungal infection after allogeneic stem cell transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Mycoses / prevention & control. Pyrimidines / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Adult. Aged. Antifungal Agents. Female. Humans. Incidence. Leukemia / complications. Leukemia / therapy. Male. Middle Aged. Transplantation, Homologous. Treatment Outcome. Voriconazole. Young Adult

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1799-805 [17786717.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):348-59 [17251531.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):245-9 [17529996.001]
  • [Cites] Clin Infect Dis. 2008 Feb 1;46(3):327-60 [18177225.001]
  • [Cites] J Antimicrob Chemother. 2008 Mar;61(3):616-20 [18222957.001]
  • [Cites] J Antimicrob Chemother. 2008 Mar;61(3):734-42 [18238891.001]
  • [Cites] Clin Microbiol Infect. 2008 May;14 Suppl 4:5-24 [18430126.001]
  • [Cites] Antimicrob Agents Chemother. 2008 May;52(5):1743-50 [18212110.001]
  • [Cites] Intern Med J. 2008 Jun;38(6b):496-520 [18588522.001]
  • [Cites] Infection. 2008 Aug;36(4):296-313 [18642109.001]
  • [Cites] Int J Antimicrob Agents. 2008 Dec;32(6):511-4 [18790613.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):97-110 [18853161.001]
  • [Cites] Clin Infect Dis. 2007 May 15;44(10):1289-97 [17443465.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4358-66 [12393425.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1122-31 [12715306.001]
  • [Cites] Bone Marrow Transplant. 2004 May;33(9):943-8 [15034546.001]
  • [Cites] Biol Blood Marrow Transplant. 2004 Jul;10(7):494-503 [15205670.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):115-21 [15156166.001]
  • [Cites] Clin Infect Dis. 1994 Apr;18(4):525-32 [8038305.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2811-4 [7919390.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):323-4 [7581159.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):297-304 [9234575.001]
  • [Cites] Clin Infect Dis. 1998 May;26(5):1098-103 [9597235.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Acta Haematol. 2005;113(2):104-8 [15802888.001]
  • [Cites] Lancet. 2005 Oct 22-28;366(9495):1435-42 [16243088.001]
  • [Cites] Clin Infect Dis. 2006 Jun 1;42(11):1584-91 [16652316.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2928-36 [16720833.001]
  • [Cites] N Engl J Med. 2007 Jan 25;356(4):335-47 [17251530.001]
  • [CommentIn] Haematologica. 2010 Oct;95(10):1630-2 [20884718.001]
  • [CommentIn] Clin Infect Dis. 2011 Sep;53(5):iii [21844020.001]
  • (PMID = 20634495.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  • [Other-IDs] NLM/ PMC2948103
  • [Investigator] Abecasis M; Rovira M; Martino R; de la Cámara R; Cordonnier C; Herbrecht R; Moreau P; Gratwohl AA; Maertens J; Cornely OA; Ljungman P; Olavarria E; Faucher C; Pigneux A; Einsele H; Ullmann AJ; Liakopoulou E; Cordonnier C; Cornely OA; Heussel CP; Rovira M; de la Cámara R
  •  go-up   go-down


79. Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, Chevallier P, Buzyn A, Delannoy A, Chalandon Y, Vernant JP, Lafage-Pochitaloff M, Chassevent A, Lhéritier V, Macintyre E, Béné MC, Ifrah N, Dombret H: Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol; 2009 Feb 20;27(6):911-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.
  • PURPOSE: Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblastic leukemia (ALL) benefit from pediatric rather than adult chemotherapy regimens.
  • Thus, the aim of the present phase II study was to test a pediatric-inspired treatment, including intensified doses of nonmyelotoxic drugs, such as prednisone, vincristine, or L-asparaginase, in adult patients with ALL up to the age of 60 years.
  • PATIENTS AND METHODS: Between 2003 and 2005, 225 adult patients (median age, 31 years; range, 15 to 60 years) with Philadelphia chromosome-negative ALL were enrolled onto the Group for Research on Adult Acute Lymphoblastic Leukemia 2003 protocol, which included several pediatric options.
  • Some adult options, such as allogeneic stem-cell transplantation for patients with high-risk ALL, were nevertheless retained.
  • RESULTS: were retrospectively compared with the historical France-Belgium Group for Lymphoblastic Acute Leukemia in Adults 94 (LALA-94) trial experience in 712 patients age 15 to 55 years.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2009 May 20;27(15):2574. Dosage error in article text
  • (PMID = 19124805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Rosenbluth MJ, Lam WA, Fletcher DA: Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry. Lab Chip; 2008 Jul;8(7):1062-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry.
  • Pathological processes in hematologic diseases originate at the single-cell level, often making measurements on individual cells more clinically relevant than population averages from bulk analysis.
  • For this reason, flow cytometry has been an effective tool for single-cell analysis of properties using light scattering and fluorescence labeling.
  • However, conventional flow cytometry cannot measure cell mechanical properties, alterations of which contribute to the pathophysiology of hematologic diseases such as sepsis, diabetic retinopathy, and sickle cell anemia.
  • Here we present a high-throughput microfluidics-based 'biophysical' flow cytometry technique that measures single-cell transit times of blood cell populations passing through in vitro capillary networks.
  • To demonstrate clinical relevance, we use this technique to characterize biophysical changes in two model disease states in which mechanical properties of cells are thought to lead to microvascular obstruction: (i) sepsis, a process in which inflammatory mediators in the bloodstream activate neutrophils and (ii) leukostasis, an often fatal and poorly understood complication of acute leukemia.
  • Using patient samples, we show that cell transit time through and occlusion of microfluidic channels is increased for both disease states compared to control samples, and we find that mechanical heterogeneity of blood cell populations is a better predictor of microvascular obstruction than average properties.
  • Altered properties of leukemia cell subpopulations, rather than of the population as a whole, were found to correlate with symptoms of leukostasis in patients-a new result that may be useful for guiding leukemia therapy.
  • [MeSH-minor] Biomechanical Phenomena. Cell Line, Tumor. Cell Movement. Cell Shape / drug effects. Cell Size / drug effects. Humans. Inflammation Mediators / pharmacology. Leukemia / complications. Leukemia / pathology. Leukostasis / complications. Leukostasis / pathology. Sepsis / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18584080.001).
  • [ISSN] 1473-0197
  • [Journal-full-title] Lab on a chip
  • [ISO-abbreviation] Lab Chip
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Inflammation Mediators
  •  go-up   go-down


81. Sutherland DR, Kuek N, Davidson J, Barth D, Chang H, Yeo E, Bamford S, Chin-Yee I, Keeney M: Diagnosing PNH with FLAER and multiparameter flow cytometry. Cytometry B Clin Cytom; 2007 May;72(3):167-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: PNH is an acquired hematopoietic stem cell disorder leading to a partial or absolute deficiency of all glycophosphatidyl-inositol (GPI)-linked proteins.
  • The classical approach to diagnosis of PNH by cytometry involves the loss of at least two GPI-linked antigens on RBCs and neutrophils.
  • Bacterial aerolysin binds to the GPI moiety of cell surface GPI-linked molecules and causes lysis of normal but not GPI-deficient PNH cells.
  • We also observed abnormal FLAER staining of blast populations in acute leukemia.
  • CONCLUSION: FLAER combined with multiparameter flow cytometry offers an improved assay for diagnosis and monitoring of PNH clones and may have utility in detection of unsuspected myeloproliferative disorders.
  • [MeSH-major] Flow Cytometry / methods. Fluorescent Dyes. Hemoglobinuria, Paroxysmal / diagnosis. Pore Forming Cytotoxic Proteins
  • [MeSH-minor] Antigens, CD / metabolism. Antigens, CD14 / metabolism. Antigens, CD45 / metabolism. Antigens, CD59 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Bacterial Toxins. Drug Stability. Erythrocytes / metabolism. Hematologic Diseases / diagnosis. Humans. Reagent Kits, Diagnostic. Sensitivity and Specificity. Sialic Acid Binding Ig-like Lectin 3

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Clinical Cytometry Society.
  • (PMID = 17285629.001).
  • [ISSN] 1552-4949
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, CD59; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Bacterial Toxins; 0 / CD33 protein, human; 0 / Fluorescent Dyes; 0 / Pore Forming Cytotoxic Proteins; 0 / Reagent Kits, Diagnostic; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / proaerolysin; 101754-01-2 / CD59 protein, human; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


82. Styczyński J, Haus O: [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults]. Postepy Hig Med Dosw (Online); 2006;60:527-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults].
  • In spite of continuous progress in the therapy of acute leukemia, relapses still occur frequently both in children and adults.
  • The presence of cytogenetic aberrations in leukemic cells at presentation is an important prognostic factor in acute leukemia.
  • The translocation t(9;22) and the 11q23/MLL rearrangement are related to poor prognosis, while hyperdiploidy >50 chromosomes and the translocation t(12;21) are indicators of good prognosis in acute lymphoblastic leukemia (ALL).
  • In acute myeloid leukemia (AML), t(8;21), t(15;17), and inv(16) indicate good prognosis, whereas 5/5q-, 7/7q-, and complex karyotype indicate poor prognosis.
  • Knowledge on the karyotype-related drug resistance profile might enable the use of targeted therapy in resistant/refractory acute leukemia both in children and adults.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060894.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins
  • [Number-of-references] 74
  •  go-up   go-down


83. Huang LB, Guan XQ, Zhang YC, Zhang XL, Ke ZY, Luo XQ: Current status of diagnosis and prognosis of infant acute leukemia in China. Pediatr Blood Cancer; 2009 Dec;53(6):973-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of diagnosis and prognosis of infant acute leukemia in China.
  • OBJECTIVE: Treatment and outcome of infant acute leukemia (IAL) in developed countries have been well documented.
  • However, reports summarizing diagnosis and outcome of IAL in developing countries are limited.
  • METHODS: Five hundred ninety seven pediatric patients were diagnosed with acute leukemia in our hospital between January 1997 and June 2008, of which 19 were younger than 12 months.
  • RESULTS: Of the 19 cases, 14 had acute lymphoblastic leukemia (ALL) and 5 had acute myeloid leukemia (AML) based on FAB classification.
  • Combining our data with those from Chinese literature, less than one third of the infants had immunophenotypic and genetic verification of leukemia and 29% (18/63) of them received treatment.
  • [MeSH-major] Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. China / epidemiology. Female. Humans. Infant. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588516.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Brière J: [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome]. Bull Acad Natl Med; 2007 Mar;191(3):535-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
  • [Transliterated title] Thrombocytémie essentielle. Apport de la mutation V617F de JAK2 pour la stratégie diagnostique, la physiopathologie et les modalités évolutives.
  • Secondary thrombocytosis is a reactive process in relation with acute or chronic inflammatory diseases, or asplenia.
  • However, the most frequent causes of chronic thrombocytosis in adults are the so-called chronic myeloproliferative syndromes (chronic myelocytic leukaemia, polycythemia vera, primary myelofibrosis, essential thrombocytemia), and to a lesser extent, myelodysplastic syndromes.
  • In the course of these disorders, thrombocytosis is often the first recognized abnormality.
  • Chronic myelocytic leukaemia is easily diagnosed owing to the presence of either the Philadelphia chromosome or the BCR-ABL fusion gene product.
  • The exclusion of PV and of IMF, including pre fibrotic and early fibrotic forms is still required for the diagnosis of "true" ET.
  • Disease stratification and treatment strategy are targeted on the evaluation and prevention of vascular complications.
  • Acute leukaemia or myelodysplasia, and other clonal progressions like myelofibrotic transformation, are infrequent and delayed events.
  • [MeSH-minor] Adult. Biopsy. Bone Marrow / pathology. Cohort Studies. Diagnosis, Differential. Disease Progression. Female. Humans. Male. Middle Aged. Mutation. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Philadelphia Chromosome. Polycythemia Vera / diagnosis. Polycythemia Vera / genetics. Primary Myelofibrosis / diagnosis. Primary Myelofibrosis / genetics. Prognosis. Risk Factors. World Health Organization

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18072652.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2
  • [Number-of-references] 56
  •  go-up   go-down


85. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P, Rosen O, Wernecke KD, Dörken B, Arnold R: Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant; 2005 Oct;36(8):683-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias.
  • To assess the role of allogeneic stem cell transplantation (SCT) after reduced-intensity conditioning (RIC) in acute leukaemias, we retrospectively compared 25 patients with acute lymphoblastic leukaemia or acute myelogenous leukaemia after RIC to a historical group of 50 matched controls after high-dose conditioning.
  • Engraftment, acute GvHD and severe infections were comparable in both groups.
  • In total, 15/25 patients (60%) relapsed after RIC and 20/50 (40%) after standard SCT; probability of disease-free survival (DFS) at 3 years was 43% after RIC and 49% after standard SCT (NS).
  • Stage of disease, cytogenetic risk profile, acute and chronic GvHD, chimerism status at day 90 and severe infections after transplantation were risk factors with significant impact on DFS and/or OS.
  • In retrospective analysis, patients with acute leukaemias who receive RIC because of contraindications against standard SCT have a comparable outcome to standard SCT, but the higher relapse rate warrants further studies.
  • [MeSH-major] Leukemia, Myeloid, Acute / therapy. Stem Cell Transplantation. Transplantation Conditioning. Transplantation, Homologous / methods
  • [MeSH-minor] Acute Disease. Adult. Disease-Free Survival. Female. Histocompatibility Testing. Humans. Living Donors. Male. Middle Aged. Neoplasm Staging. Survival Analysis


86. Belacel N, Wang Q, Richard R: Web-integration PROAFTN methodology for acute leukemia diagnosis. Telemed J E Health; 2005 Dec;11(6):652-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Web-integration PROAFTN methodology for acute leukemia diagnosis.
  • OBJECTIVE: To develop and test a web-based Clinical Decision Support System (CDSS) tool, which integrated a new fuzzy multiple criteria classification methodology named PROAFTN in acute leukemia (AL) diagnosis.
  • 1) make a "virtual" diagnosis and to compare its performances with given clinical diagnosis;.
  • The method will not replace specialists, but was developed to assist biologist-hematologists and general practitioners remotely in making decisions on medical diagnosis.
  • [MeSH-major] Decision Support Systems, Clinical / organization & administration. Internet. Leukemia / diagnosis. Systems Integration
  • [MeSH-minor] Acute Disease. Humans. New Brunswick. Software

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430384.001).
  • [ISSN] 1530-5627
  • [Journal-full-title] Telemedicine journal and e-health : the official journal of the American Telemedicine Association
  • [ISO-abbreviation] Telemed J E Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Kaya P, Gündüz U, Arpaci F, Ural AU, Guran S: Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients. Am J Hematol; 2005 Sep;80(1):26-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of polymorphisms on the MDR1 gene among Turkish population and their effects on multidrug resistance in acute leukemia patients.
  • Multidrug-resistance (MDR) phenotype is a serious limitation to the effective chemotherapeutic treatment of many cancer types, including leukemia.
  • The frequencies of these SNPs were studied in 45 acute leukemia patients (25 of which were primary refractory and 20 of which were drug-sensitive) and 17 healthy individuals, forming a Turkish population of 62 individuals.
  • In the second part of this study, drug-resistant and drug-sensitive acute leukemia patients were compared for these SNPs.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Leukemia / genetics. P-Glycoprotein / genetics. Polymorphism, Genetic. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Antigens, CD / immunology. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Humans. Immunophenotyping. Reference Values. Turkey

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16138358.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Neoplasm; 0 / P-Glycoprotein
  •  go-up   go-down


88. Liedtke M, Cleary ML: Therapeutic targeting of MLL. Blood; 2009 Jun 11;113(24):6061-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of hematologic malignancies is evolving from a uniform approach to targeted therapies directed at the underlying molecular abnormalities of disease.
  • The mixed lineage leukemia (MLL) proto-oncogene is a recurrent site of genetic rearrangements in acute leukemias; and since its discovery in 1992, many advances have been made in understanding its role in leukemogenesis.
  • Proteins associated with the MLL core complex or its fusion partners have been isolated and characterized for their critical roles in leukemia pathogenesis.
  • [MeSH-major] Leukemia / therapy. Myeloid-Lymphoid Leukemia Protein / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6236-9 [8016145.001]
  • [Cites] Bioessays. 1995 Oct;17(10):855-63 [7487967.001]
  • [Cites] Nature. 1995 Nov 30;378(6556):505-8 [7477409.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12160-4 [8618864.001]
  • [Cites] Science. 1997 Apr 18;276(5311):404-7 [9103196.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1799-806 [9292512.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):122-9 [9418860.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6723-9 [9822615.001]
  • [Cites] Leukemia. 1999 Oct;13(10):1525-33 [10516753.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(23):10470-8 [15542854.001]
  • [Cites] Blood. 2005 Jan 15;105(2):812-20 [15374878.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 [15640349.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] Leukemia. 2006 Jul;20(7):1307-10 [16617320.001]
  • [Cites] Blood. 2006 Jul 15;108(2):622-9 [16469876.001]
  • [Cites] Leuk Res. 2008 Apr;32(4):633-42 [17875318.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3651-6 [18559577.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):36-46 [18598942.001]
  • [Cites] PLoS Genet. 2008;4(9):e1000190 [18787701.001]
  • [Cites] Nature. 2008 Oct 30;455(7217):1205-9 [18806775.001]
  • [Cites] Trends Cell Biol. 2000 Apr;10(4):147-54 [10740269.001]
  • [Cites] EMBO J. 2000 Sep 1;19(17):4655-64 [10970858.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6227-9 [11103774.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):315-26 [11167824.001]
  • [Cites] Br J Haematol. 2001 Feb;112(2):358-63 [11167829.001]
  • [Cites] Oncogene. 2001 Feb 15;20(7):874-8 [11314021.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] Leukemia. 2006 Aug;20(8):1368-76 [16761017.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] EMBO J. 2006 Oct 4;25(19):4503-12 [16990798.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):175-88 [15826832.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):919-29 [15761502.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Blood. 2005 Jul 1;106(1):345-52 [15774615.001]
  • [Cites] Blood. 2005 Jul 15;106(2):706-12 [15802527.001]
  • [Cites] Genes Dev. 2005 Aug 15;19(16):1885-93 [16103216.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1605-12 [16034464.001]
  • [Cites] Cell. 2005 Oct 21;123(2):207-18 [16239140.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11367-74 [16357144.001]
  • [Cites] Nat Med. 2006 Jan;12(1):89-98 [16341242.001]
  • [Cites] Leukemia. 2006 Feb;20(2):264-71 [16357833.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):539-51 [16445826.001]
  • [Cites] J Proteome Res. 2006 Oct;5(10):2743-53 [17022645.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):257-68 [17045204.001]
  • [Cites] Hum Mol Genet. 2007 Jan 1;16(1):92-106 [17135274.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7275-83 [17671196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14442-7 [17726105.001]
  • [Cites] Nat Cell Biol. 2007 Oct;9(10):1208-15 [17891136.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6766-76 [17934484.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2762-74 [17942707.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4445-54 [17855633.001]
  • [Cites] Leukemia. 2008 Jan;22(1):66-77 [17851551.001]
  • [Cites] Genome Biol. 2002;3(1):REVIEWS3001 [11806834.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):958-65 [11842107.001]
  • [Cites] Blood. 2002 May 15;99(10):3780-5 [11986236.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):1052-8 [12123582.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1270-6 [12406912.001]
  • [Cites] J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86 [12615961.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):173-83 [12620411.001]
  • [Cites] Cell. 2003 Mar 7;112(5):711-23 [12628190.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):99-110 [12957285.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2298-307 [12952893.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):197-207 [14522254.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):19-23 [14630076.001]
  • [Cites] Mol Cell Biol. 2004 Jan;24(2):617-28 [14701735.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1823-8 [14615372.001]
  • [Cites] Mol Cell. 2004 Feb 27;13(4):587-97 [14992727.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3192-9 [15070702.001]
  • [Cites] Blood. 2004 May 15;103(10):3876-82 [14751928.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):5639-49 [15199122.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1364-72 [15269783.001]
  • [Cites] Leuk Lymphoma. 2004 May;45(5):1017-24 [15291362.001]
  • [Cites] Cell. 1992 Nov 13;71(4):691-700 [1423624.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • (PMID = 19289854.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA120349
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 78
  • [Other-IDs] NLM/ PMC2699228
  •  go-up   go-down


89. Rudant J, Menegaux F, Leverger G, Baruchel A, Nelken B, Bertrand Y, Hartmann O, Pacquement H, Vérité C, Robert A, Michel G, Margueritte G, Gandemer V, Hémon D, Clavel J: Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: the ESCALE study (SFCE). Int J Cancer; 2007 Jul 1;121(1):119-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of cancer in children with acute leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma: the ESCALE study (SFCE).
  • The role of a family history of cancer in the etiology of childhood hematopoietic malignancies was investigated using the data from the ESCALE study.
  • A total of 773 cases of acute leukemia (AL), 130 of Hodgkin's lymphoma (HL), 163 of non-Hodgkin's lymphoma (NHL) and 1,681 population-based controls were included.
  • Only HL was significantly associated with a family history of hematopoietic malignancies (OR = 2.0 [1.0-3.8]), mainly because of a significant association with a history of HL (OR = 5.4 [1.3-22]).
  • [MeSH-major] Hodgkin Disease / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Lymphoma, Non-Hodgkin / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Child, Preschool. Disease Susceptibility / classification. Disease Susceptibility / epidemiology. Disease Susceptibility / pathology. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Odds Ratio

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330239.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


90. Farsi Z, Dehghan Nayeri N, Negarandeh R: Coping strategies of adults with leukemia undergoing hematopoietic stem cell transplantation in Iran: a qualitative study. Nurs Health Sci; 2010 Dec;12(4):485-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coping strategies of adults with leukemia undergoing hematopoietic stem cell transplantation in Iran: a qualitative study.
  • Hematopoietic stem cell transplantation (HSCT) causes significant physical, social, psychological, and emotional stress in patients with leukemia.
  • This qualitative study using semi-structured interviews explored the coping strategies of 10 adults with acute leukemia who were undergoing this form of treatment in transplantation units in a major hospital in Tehran, Iran, from 2009 to 2010.
  • A deeper understanding of the coping strategies that are used by patients with leukemia undergoing HSCT can help healthcare providers to encourage patients to use strategies that are likely to be more effective.
  • [MeSH-major] Adaptation, Psychological. Attitude to Health. Hematopoietic Stem Cell Transplantation / psychology. Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Asia Pty Ltd.
  • (PMID = 21210928.001).
  • [ISSN] 1442-2018
  • [Journal-full-title] Nursing & health sciences
  • [ISO-abbreviation] Nurs Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


91. Chen X, Zhang Y, Li Y, Lei P, Zhai Y, Liu L: Biphenotypic hematologic malignancy: a case report of the 8p11 myeloproliferative syndrome in a child. J Pediatr Hematol Oncol; 2010 Aug;32(6):501-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: The 8p11 myeloproliferative syndrome, also known as stem cell leukemia/lymphoma, is a rare, atypical, myeloproliferative disorder and lymphoid malignancy associated with chromosomal abnormalities involving the 8p11 chromosomal band.
  • Disease phenotypes associated with this translocation include poor prognosis and transformation to acute leukemia and non-Hodgkin lymphoma.
  • In common with a T-cell phenotype, obtaining and maintaining remission is difficult by conventional chemotherapy.
  • This study describes an illustrative case of 8p11 myeloproliferative syndrome/stem cell leukemia/lymphoma outlining its chief features and historical developments.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Male. Phenotype. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / physiopathology. Prednisone / therapeutic use. Syndrome. Translocation, Genetic. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562652.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CVAD protocol; EPOCH protocol
  •  go-up   go-down


92. Musil D, Krc I: Migrating venous thrombosis in acute leukemia. Blood Coagul Fibrinolysis; 2010 Jun;21(4):365-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Migrating venous thrombosis in acute leukemia.
  • We present a 55-year-old man with acute migrating thrombophlebitis and deep vein thrombosis of muscle veins in both calves indicating occurrence of acute myelomonocytic leukemia.
  • [MeSH-major] Leukemia, Myelomonocytic, Acute / complications. Venous Thrombosis / complications

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • Hazardous Substances Data Bank. WARFARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20305540.001).
  • [ISSN] 1473-5733
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 5Q7ZVV76EI / Warfarin
  •  go-up   go-down


93. Ren CM, Luo WD, Feng CW: [One case of benzene induced acute leukemia]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2009 Jan;27(1):20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [One case of benzene induced acute leukemia].
  • [MeSH-major] Benzene / poisoning. Leukemia / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Acute Disease. Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224687.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] J64922108F / Benzene
  •  go-up   go-down


94. Li XL, Li R, Chen Y: [Clinical characteristics and immunophenotypes of mixed-lineage acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Jun;15(3):636-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and immunophenotypes of mixed-lineage acute leukemia].
  • The aim of study was to analyze the clinical, biological features, treatment outcome and prognosis of mixed-lineage acute leukemia (MAL).
  • 48 MAL patients diagnosed according to European Group of International Leukemia (EGIL) scoring system were retrospectively analyzed and the analysis results were compared with that from 68 cases of AML and 61 cases of ALL.
  • The results showed that the incidence of MAL in acute leukemia was 9.6%.
  • Morphologically, the subtypes of M(1) and M(2) were predominant in AML, while L(2) in ALL.
  • The median of white blood cell count in MAL was significantly higher than that of non-mixed-lineage cases (AML and ALL) observed during the same period (P < 0.05).
  • In MAL Ph chromosome abnormality incidence was 25% and was significantly higher than that in AML group (0%) (P < 0.01), but was not statistical defference with that in ALL group (16.7%) (P > 0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17605883.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


95. Gupta V, Tripathi S, Tilak V, Bhatia BD: A study of clinico-haematological profiles of pancytopenia in children. Trop Doct; 2008 Oct;38(4):241-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aplastic anaemia was the most common cause of pancytopenia (43%) followed by acute leukaemia (25%).
  • [MeSH-minor] Adolescent. Anemia, Aplastic / complications. Child. Child, Preschool. Female. Humans. Infant. Leishmaniasis, Visceral / complications. Leukemia / complications. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820199.001).
  • [ISSN] 0049-4755
  • [Journal-full-title] Tropical doctor
  • [ISO-abbreviation] Trop Doct
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Parry TE: Mutagenic mechanisms in leukemia and cancer: a new concept Cytosine lack could be as mutagenic as cytosine deamination. Leuk Res; 2006 Sep;30(9):1079-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutagenic mechanisms in leukemia and cancer: a new concept Cytosine lack could be as mutagenic as cytosine deamination.
  • All three mutagens lead to a G=C --> A=T point mutation in the DNA molecule and the biochemical basis of these mutations in each case is the deamination of cytosine to uracil.
  • It is shown that the lack of cytosine could be as mutagenic as the deamination of cytosine and it is shown schematically how cytosine lack could give rise to a population of genetically abnormal cells which are completely incapable of any degree of differentiation; a state perhaps reminiscent of the most acute of leukemias and the most anaplastic of cancers.
  • [MeSH-major] Cytosine. DNA Methylation. DNA Repair / genetics. Leukemia / genetics. Point Mutation

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820204.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 56HH86ZVCT / Uracil; 8J337D1HZY / Cytosine
  • [Number-of-references] 29
  •  go-up   go-down


97. Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA. Best Pract Res Clin Haematol; 2008 Mar;21(1):1-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the biology and therapy of acute myelogenous leukemia. Selection of keynote addresses from the Acute Leukemia Forum 2007. March 23, 2007. San Francisco, California, USA.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Leukemia, Myeloid, Acute / therapy

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561374.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] England
  •  go-up   go-down


98. Horikoshi Y, Kobayashi R, Endo M, Watanabe A, Kikuta A, Koike K, Hanada R, Hosoya R, Ohara A, Ikuta K, Goto H, Asami K, Sugita K, Horibe K, Tsurusawa M, Hori T, Hara J, Nishimura S, Nagatoshi Y, Mugishima H, Ohta S, Adachi S, Tsukimoto I: [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia]. Rinsho Ketsueki; 2010 Feb;51(2):104-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effectiveness of remission induction with high-dose cytarabine for relapsed or refractory pediatric acute leukemia].
  • We conducted a multicenter postmarketing study to investigate the efficacy and safety of reinduction therapy with a high-dose cytarabine-containing regimen for pediatric patients with relapsed or refractory acute leukemia.
  • The frequent non-hematologic adverse events were gastrointestinal toxicities, such as vomiting, diarrhea and abdominal pain, as well as pyrexia and headache.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Invasive Pulmonary Aspergillosis / etiology. Invasive Pulmonary Aspergillosis / prevention & control. Leukemia, Myeloid, Acute / drug therapy. Male. Pulse Therapy, Drug. Recurrence. Remission Induction. Treatment Outcome

  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379101.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


99. Hale KA, Shaw PJ, Dalla-Pozza L, MacIntyre CR, Isaacs D, Sorrell TC: Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant. Br J Haematol; 2010 Apr;149(2):263-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of paediatric invasive fungal infections and a case-control study of risk factors in acute leukaemia or post stem cell transplant.
  • Cases with an underlying diagnosis of acute leukaemia or following stem cell transplantation were included in a case control study.
  • Controls included all other children with acute leukaemia or stem cell transplant in the corresponding time period.
  • Variables collected included demographics, underlying disease risk and status, organ impairment, admission to intensive care unit, fungal infection details and certain transplant variables.
  • The incidence of invasive fungal infection was 21% in acute lymphoblastic leukaemia, 15% in acute myeloid leukaemia and 25% following stem cell transplantation.
  • Sixty per cent were neutropenic at diagnosis and 39% had concomitant bacteremia.
  • High risk acute lymphoblastic leukaemia, relapsed disease, intensive care admission and graft-versus-host disease were significantly associated with development of invasive fungal infection on multivariate analysis.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia / epidemiology. Mycoses / epidemiology. Opportunistic Infections / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Case-Control Studies. Child. Child, Preschool. Cross Infection / complications. Cross Infection / epidemiology. Cross Infection / immunology. Graft vs Host Disease / complications. Graft vs Host Disease / epidemiology. Humans. Immunocompromised Host. Infant. Infant, Newborn. New South Wales / epidemiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20096013.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Nivison-Smith I, Simpson JM, Dodds AJ, Ma DD, Szer J, Bradstock KF: Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates. Biol Blood Marrow Transplant; 2009 Oct;15(10):1323-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative survival of long-term hematopoietic cell transplant recipients approaches general population rates.
  • Whether the annual mortality rates of long-term hematopoietic cell transplant (HCT) survivors ever return to that of the general population is unclear.
  • This study sought to determine the annual long-term mortality rates of allogeneic and autologous HCT recipients who had survived 5 years or more disease-free posttransplant and calculate their relative survival rates.
  • Patients were included if they had a first allogeneic or syngeneic HCT for acute leukemia, chronic myelogenous leukemia (CML) or myelodysplastic syndromes (MDS), or autologous HCT for acute myelogenous leukemia (AML) or lymphoma in Australia or New Zealand between 1992 and 2001, recorded on the Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) database, and were known to have survived, disease free, 5 years or more posttransplant.
  • This study indicates that annual relative survival rates of long-term survivors of allogeneic HCT performed in Australia and New Zealand for acute lymophoblastic leukemkia (ALL), AML, CML, and MDS are slightly, but significantly lower than population rates in the 6th to 10th years posttransplant.
  • Late deaths from transplant and disease-related causes are unusual, but continue to occur for many years post-HCT.
  • [MeSH-major] Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation. Registries
  • [MeSH-minor] Adolescent. Adult. Australia. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Middle Aged. New Zealand. Retrospective Studies. Survival Rate. Time Factors. Transplantation, Autologous. Transplantation, Homologous

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19747641.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement